 

 

 

 

 

 

 

Protection of Privacy and Confidentiality 

This is a cover page for an Eli Lilly and Company document that has been redacted for either 
Personal Information (PI) or Commercially/Company Confidential Information (CCI) or both. 
Within this document PI or CCI is either removed (pages deleted) or redacted (specific content is 
irreversibly deleted and replaced with a black bar or box) to protect personal privacy or 
intellectual property. 

Redacted Version 

Eli Lilly and Company 

Redacted Version Approval Date: 07-Mar-2016 GMTPage 1 

Confidential Information 

The information contained in this protocol is confidential and is intended for the 
use of clinical investigators.  It is the property of Eli Lilly and Company or its 
subsidiaries and should not be copied by or distributed to persons not involved in 
the clinical investigation of pemetrexed (LY231514), unless such persons are 
bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries. 

Protocol H3E-MC-JMHR(b) 

A Randomized Phase 3 Study of Pemetrexed in 

Combination with Cisplatin Versus Cisplatin 

Monotherapy in Patients with Recurrent or Metastatic 

Head and Neck Cancer 

Alimta®

 

(pemetrexed, LY231514) 

A Phase 3, randomized, doub e-bl nd study of pemetrexed and cisplatin versus 
cisplatin monotherapy in patients with recurrent or metastatic head and neck 
cancer. 

Eli Lilly and Company 

Indianapolis, Indiana USA 46285 

Protocol Approved by Lilly:  31 May 2006 

Amendment (a) Approved by Lilly:  10 August 2007 

Amendment (b) Approved by Lilly:  16 July 2008 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 2 

A Randomized Phase 3 Study of Pemetrexed in 

Combination with Cisplatin Versus Cisplatin 

Monotherapy in Patients with Recurrent or Metastatic 

Head and Neck Cancer 

Section 

Page 

Table of Contents 

1. 

1.2.1. 
1.2.2. 

1.2.3. 

Introduction....................................................................................... 12 
1.1. 
Indication ..................................................................................... 12 
1.2.  Study Rationale ............................................................................ 12 
Head and Neck Cancer:  Disease Overview .......................... 12 
Chemotherapy in the Treatment of Head and Neck 
Cancer........................................................
Rationale for Use of Pemetrexed in Head and Neck 
Cancer................................................ ................................. 14 
.. .................................. 14 
....................................... 15 
Single-Agent Pemetrexed.......................................... 15 
Pemetrexed Plus Cisplatin......................................... 16 

1.2.3.1.  Mechanism of Action........... ...
1.2.3.2.  Development of Pemetrexed .

1.2.3.2.1. 
1.2.3.2.2. 

...

................... 12 

1.2.3.3.  Development of Pemetrexed for Patients with 

Head and Neck Cancer.................................................... 18 

1.2.3.3.1. 

1.2.3.3.2. 

Single-Agent Pemetrexed for Patients with 
Head and Neck Cancer.............................................. 18 
Pemetrexed Plus Cisplatin for Patients with 
Head and Neck Cancer.............................................. 18 
Summary and Conclusions.............................................. 18 

1.2.3.4. 

2.  Objectives ......................................................................................... 20 
2.1.  Primary Objective ........................................................................ 20 
2.2.  Secondary Objectives ................................................................... 20 

3. 

Investigational Plan ........................................................................... 21 
3.1.  Summary of Study Design............................................................ 21 
3.2.  Discussion of Design and Control................................................. 22 

4.  Study Population ............................................................................... 24 
Inclusion Criteria.......................................................................... 24 
4.1. 
4.2.  Exclusion Criteria......................................................................... 25 
Rationale for Exclusion of Certain Study Candidates............ 26 

4.2.1. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version 4.3.  Discontinuations........................................................................... 26 

Page 3 

5.2.1. 
5.2.2. 
5.2.3. 
5.2.4. 
5.2.5. 
5.2.6. 

5.  Treatment.......................................................................................... 28 
5.1.  Treatments Administered.............................................................. 28 
5.2.  Materials and Supplies.................................................................. 28 
Pemetrexed (Treatment Arm A) ........................................... 28 
Cisplatin (Both Treatment Arms).......................................... 29 
Placebo (Treatment Arm B).................................................. 29 
Folic Acid (Both Treatment Arms) ....................................... 29 
Vitamin B12 (Both Treatment Arms) ................................... 30 
Dexamethasone (Both Treatment Arms)............................... 30 
5.3.  Method of Assignment to Treatment............................................. 30 
5.4.  Rationale for Selection of Doses in the Study ............................... 31 
................. 31 
................. 31 
.. ...................... 32 
Special Treatment Considerations.....
...... ........................... 33 
Dose Adjustments or Delays for Subsequent Cycles ............. 33 
5.5.2.1.  Hematologic Adverse Events . ........................................ 34 
5.5.2.2.  Nonhematologic Adverse Events .................................... 34 
5.5.2.3. 
.. ................................................. 35 
5.5.2.4.  Dose Adjustments for Neurosensory Adverse 

Cisplatin...........................................................
Pemetrexed in Combination with Cisplatin..
..
5.5.  Selection and Timing of Doses ..........................

Creatinine Clearance.

5.5.1. 
5.5.2. 

5.4.1. 
5.4.2. 

... ..

5.5.2.5. 

Events............. .... .......................................................... 36 
Treatment Delays Due to Insufficient Folic Acid 
or Vitamin B12 Supplementation .................................... 36 
5.6.  Blinding .
......................................................................... 36 
5.7.  Concomitant Therapy ................................................................... 37 
Colony Stimulating Factors .................................................. 37 
Nonsteroidal Anti-Inflammatory Drugs ................................ 38 
Leucovorin ........................................................................... 38 
Therapy for Diarrhea ............................................................ 38 
Therapy for Febrile Neutropenia........................................... 39 
Clinically Significant Effusions ............................................ 39 
5.8.  Treatment Compliance ................................................................. 39 

5.7.1. 
5.7.2. 
5.7.3. 
5.7.4. 
5.7.5. 
5.7.6. 

6.  Efficacy, Health Outcome/Quality of Life Measures, and 

Safety Evaluations............................................................................. 40 
6.1.  Efficacy Measures ........................................................................ 40 
Timing of Measurements...................................................... 40 
Baseline and Study Treatment Periods ............................ 40 

6.1.1.1. 

6.1.1. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 4 

6.1.2.1. 

6.1.1.2. 

Postdiscontinuation Period.............................................. 40 
Efficacy Criteria for Tumor Response .................................. 41 
Best Response................................................................. 41 
Definition of Efficacy Measures ........................................... 41 
6.2.  Health Outcome/Quality-of-Life Measures ................................... 42 
6.3.  Safety Evaluations........................................................................ 44 
Adverse Events .................................................................... 44 
Clinical Adverse Events.................................................. 44 
Serious Adverse Events .................................................. 45 
Postdiscontinuation Safety Follow-Up ............................ 46 
Laboratory Tests................................................................... 46 

6.3.1.1. 
6.3.1.2. 
6.3.1.3. 

6.3.1. 

6.1.2. 

6.1.3. 

6.3.2. 

6.3.2.1. 

6.3.2.2. 

6.3.2.2.1. 
6.3.2.2.2. 

Limited Use Samples for Standard Laboratory 
Testing............................................................................ 47 
....
Samples for Translational Research ..........
.............. 47 
Stored Samples ........................... ... ....
................... 48 
.......................... 48 
Collection Procedures .............. ..
..
................................ 48 
................................... 49 
................................................... 49 
6.4.  Appropriateness of Measurements .............................................. 49 

Other Safety Measures ..................
Safety Monitoring .....................
...
Complaint Handling ........

6.3.3. 
6.3.4. 
6.3.5. 

7.  Data Quality Assurance........

..................................................... 50 
7.1.  Data Entry and Computerized Systems ......................................... 50 

...

8.  Sample Size and Statistical Methods ................................................. 51 
8.1.  Determination of Sample Size ...................................................... 51 
8.2.  Statistical and Analytical Plans..................................................... 51 
General Considerations ........................................................ 51 
8.2.1.1.  Qualifications for Efficacy Analysis................................ 52 
8.2.1.2.  Qualifications for Health Outcome/Quality-of-

8.2.1. 

8.2.2. 
8.2.3. 
8.2.4. 
8.2.5. 
8.2.6. 

Life Analysis .................................................................. 52 
8.2.1.3.  Qualifications for Safety Analysis................................... 52 
Patient Disposition ............................................................... 52 
Patient Characteristics .......................................................... 52 
Concomitant Therapy ........................................................... 53 
Treatment Compliance ......................................................... 53 
Efficacy Analyses................................................................. 53 
Primary Outcome and Methodology................................ 53 
Secondary Endpoints ...................................................... 53 
Quality-of-Life Analysis....................................................... 54 

8.2.6.1. 
8.2.6.2. 

8.2.7. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 5 

8.2.8. 

Statistical Strategy for Analyzing Selected Efficacy 
Endpoints ............................................................................. 55 
8.2.9. 
Safety Analyses.................................................................... 55 
8.2.10.  Subgroup Analyses............................................................... 55 
8.2.11. 
Interim Analyses .................................................................. 56 
8.2.12.  Criteria for End of Study ...................................................... 57 
8.2.13.  Translational Research Analyses .......................................... 57 

9. 

Informed Consent, Ethical Review, and Regulatory 
Considerations................................................................................... 59 
9.1. 
Informed Consent ......................................................................... 59 
9.2.  Ethical Review ............................................................................. 59 
9.3.  Regulatory Considerations............................................................ 60 
Investigator Information ....................................................... 60 
Protocol Signatures .........................................
.... .............. 60 
Final Report Signature.............................. .. ... .................... 60 

9.3.1. 
9.3.2. 
9.3.3. 

10.  References.....................................................

...... ........................... 61 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Table of Contents (concluded) 

Page 6 

 
List of Protocol Attachments 

Protocol Attachment JMHR.1. 

Study Schedule 

Protocol Attachment JMHR.2. 
Clinical Laboratory Tests 

Protocol Attachment JMHR.3. 

ECOG Performance Status Scale 

Protocol Attachment JMHR.4. 

Creatinine Clearance Assay Methods 

Protocol Attachment JMHR.5. 

RECIST Guidelines 

Protocol Attachment JMHR.6. 

Functional Assessment of Cancer Therapy - 
Head and Neck Cancer (FACT-H&N) 

Protocol Attachment JMHR.7. 

Formula for Conditional Power 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Abbreviations and Definitions 

Page 7 

ALP 

ALT 

ANC 

ASCO 

AST 

Assent 

Audit 

Blinding/Masking 

CNS 

Complaint 

Compliance 

Confirmation 

alkaline phosphatase 

alanine aminotransferase 

absolute neutrophil count 

American Society of Clinical Oncology 

aspartate aminotransferase 

Agreement from a child or other individual who is not legally capable of 
providing consent, but who can understand the circumstances and risks involved 
in participating in a study (required by some Institutional Review Boards 
[IRBs]).  

A systematic and independent examination of th  trial-related activities and 
documents to determine whether the evaluated trial-related activities were 
conducted, and the data were recorded, ana yzed, and accurately reported 
according to the protocol, applicable standard operating procedures (SOPs), 
good clinical practice (GCP), and the applicable regulatory requirement(s). 

A procedure in which one or more parties to the trial are kept unaware of the 
treatment assignment(s).  Single-blinding usually refers to the subject(s) being 
unaware, and double blinding usually refers to the subject(s), investigator(s), 
monitor(s), and in some cases, select sponsor personnel being unaware of the 
treatment assignment(s). 

central nervous system 

A complaint is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, purity, durability, reliability, safety 
or effectiveness, or performance of a drug or drug delivery system. 

Adherence to all the trial-related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory requirements. 

A process used to confirm that laboratory test results meet the quality 
requirements defined by the laboratory generating the data and that Lilly is 
confident that results are accurate.  Confirmation will either occur immediately 
after initial testing or will require that samples be held to be retested at some 
defined time point, depending on the steps required to obtain confirmed results. 

CR 

CrCl 

complete response 

creatinine clearance 

(continued) 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Abbreviations and Definitions (Continued) 

Page 8 

CRF 

CRP 

CSF 

CT 

CTC 

Case Report Form (sometimes referred to as Clinical Report Form).  A printed 
or electronic form for recording study participants’ data during a clinical study, 
as required by the protocol. 

clinical research physician 

colony stimulating factor 

computed tomography 

Common Toxicity Criteria 

CTCAE 

Common Terminology Criteria for Adverse Events 

DHFR 

DLTs 

DMB 

DNA 

DoR 

ECOG 

ERCC1 

EU 

dihydrofolate reductase 

dose-limiting toxicities 

Data Monitoring Board 

deoxyribonucleic acid 

duration of response 

Eastern Cooperative Oncology Group 

excision-repair cross-complementing rodent repair deficiency 

European Union 

End of Study 
(Trial) 

End of study (trial) will occur when data collection for the study is completed. 
(See Section 8.2.12 for further details about criteria for study termination.) 

FACT-H&N 

Functional Assessment of Cancer Therapy - Head and Neck Cancer 

formalin-fixed, paraffin-embedded 

folylpolyglutamyl synthetase 

folate receptor-alpha 

glycinamide ribonucleotide formyltransferase 

granulocyte colony-stimulating factor 

glomerular filtration rate 

Global Product Safety 

hemoglobin 

FFPE 

FPGS 

FR-α 

GARFT 

G-CSF 

GFR 

GPS 

Hgb 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

(continued) 

Protocol Amendment 

Redacted Version Page 9 

Abbreviations and Definitions (Continued) 

HNC 

HRQoL 

HR 

IHC 

head and neck cancer 

health-related quality of life 

hazard ratio 

immunohistochemical 

Interim Analysis 

Any analysis intended to compare treatment groups at any time prior to the 
formal completion of a trial. 

Intention to Treat 
(ITT) 

Investigator 

IRB/ERB 

The principle that asserts that the effect of a treatment policy can be best 
assessed by evaluating on the basis of the intention to treat a subject (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that subjects allocated to a treatment group should be followed up, 
assessed and analyzed as members of that group irrespective of their compliance 
to the planned course of treatment. 

A person responsible for the conduct of the clini al trial at a trial site.  If a trial 
is conducted by a team of individuals at a trial site, the investigator is the 
responsible leader of the team and may be called the principal investigator. 

Institutional review board/ethical review board:  a board or committee 
(institutional, regional, or national) composed of medical professional and 
nonmedical members whose responsibility is to verify that the safety, welfare, 
and human rights of the subjects participating in a clinical trial are protected. 

IUD 

IVRS 

K-M 

intrauterine device 

interactive voice response system 

Kaplan-Meier 

Legal 
Representative 

An individual, judicial, or other body authorized under applicable law to 
consent, on behalf of a prospective subject, to the patient's participation in the 
clinical trial. 

LSMeans 

least square means 

MID 

MPM 

MQA 

MRI 

MTD 

NCI 

minimally important difference 

malignant pleural mesothelioma 

Medical Quality Assurance 

magnetic resonance imaging 

maximum tolerated dose 

National Cancer Institute 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

(continued) 

Protocol Amendment 

Redacted Version Abbreviations and Definitions (Continued) 

Page 10 

NSAIDs 

NSCLC 

ORR 

OS 

Patient 

PD 

PET 

PFS 

PR 

RECIST 

REML 

SAC 

SAE 

SD 

nonsteroidal anti-inflammatory drugs 

non-small cell lung cancer 

overall response rate 

overall survival 

A subject with a defined disease. 

progressive disease 

positron emission tomography 

progression-free survival 

partial response 

Response Evaluation Criteria in Solid Tumors 

restricted maximum likelihood method 

Statistical Analysis Center 

serious adverse event 

stable disease 

Study Entry Terms  Enter/Consent 

The act of obtaining informed consent for participation in a clinical trial from 
individuals deemed potentially eligible to participate in the clinical trial.  
Individuals entered into a trial are those who sign the informed consent 
document directly or through their legally acceptable representatives. 

Registration 
The act of assigning a registration number to the patient indicating that the 
investigator has verified that the patient meets the inclusion criteria and none of 
the exclusion criteria. 

Enroll/Randomize 
The act of assigning a patient to a treatment.  Patients who are enrolled in the 
trial are those who have been assigned to a treatment. 

Trial Outcome Index 

translational research 

TOI 

TR 

 

(continued) 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 11 

Abbreviations and Definitions (Concluded) 

Treatment-
Emergent Adverse 
Event (TEAE) 

Any untoward medical occurrence that either occurs or worsens at any time after 
treatment baseline and which does not necessarily have to have a causal 
relationship with this treatment (also called treatment-emergent signs and 
symptoms [TESS]). 

TS 

TTW 

ULN 

US 

 

thymidylate synthase 

time to worsening 

upper limit of normal 

United States 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 12 

A Randomized Phase 3 Study of Pemetrexed in 

Combination with Cisplatin Versus Cisplatin 

Monotherapy in Patients with Recurrent or Metastatic 

Head and Neck Cancer 

1. 

Introduction 

Indication 

1.1. 
Head and neck cancer (HNC) that is recurrent and not amenable to local therapy (surgery 
or radiation) or newly diagnosed distant metastatic disease. 

1.2.  Study Rationale 

1.2.1.  Head and Neck Cancer:  Disease Overview 
Head and neck cancer refers to a heterogeneous collection of malignancies arising in the 
upper aerodigestive tract, including squamous cell carcinomas of the oral cavity (buccal 
mucosa, upper and lower alveolar ridges, retromolar trigone, hard palate, anterior 
two-thirds of the tongue, and the floor of the mouth), pharynx (nasopharynx, oropharynx, 
and hypopharynx), and larynx. 

The most common risk factors for HNC are tobacco and alcohol use, with concomitant 
use conferring even higher risk   Occupational risk factors include nickel refining, 
woodworking, and exposure to textile fibers.  Additionally, DNA from the Epstein-Barr 
virus has been identified in human nasopharyngeal cancer tissue, and DNA from the 
human papilloma virus has been identified in more than 50% of oropharyngeal cancer 
tissues (Forastiere et al. 2001). 

1.2.2.  Chemotherapy in the Treatment of Head and Neck Cancer 
Recurrent and metastatic head and neck squamous cell cancers are generally incurable 
and are associated with poor survival.  Palliative chemotherapy is usually offered to 
patients with recurrent or distant metastatic disease that is recognized as incurable and 
not amenable to local therapy.  The median survival with chemotherapy is approximately 
6 months, with a 1-year survival rate of approximately 20% (Forastiere et al. 2005). 

Until the early 1980s, single-agent methotrexate (with response rates of 10% to 35% and 
median duration of response of approximately 2 to 5 months) was the standard agent for 
palliation of patients with advanced HNC.  Two small, randomized trials later established 
that cisplatin monotherapy has efficacy comparable with that of methotrexate 
monotherapy (based on response rate and median response duration), as well as a 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 13 

manageable toxicity profile in patients with advanced HNC (Hong et al. 1983; Grose et 
al. 1985). 

In 1985, Morton and colleagues reported the results of a Phase 3 study in which 
116 patients with advanced HNC were randomized to 4 treatment arms:  (1) no active 
treatment (control) (2) cisplatin 100 mg/m2 every month (3) bleomycin 15 mg/day for 5 
consecutive days every month or (4) the combination arm of cisplatin 100 mg/m2 every 
month plus bleomycin 15 mg/day for 5 consecutive days every month (Morton et al. 
1985).  The primary aim of this study was to demonstrate a significant prolongation of 
the 11-week median survival in this group of patients.  In this study, the only significant 
prolongations of survival were for the 2 groups receiving cisplatin (single-agent cisplatin 
versus control, p<0.05; two cisplatin arms versus 2 noncisplatin arms, p<0.01), with a 
prolongation of median survival by 10 weeks.  Single-agent cisplatin almost reached 
significance over cisplatin plus bleomycin combination therapy (p=0.065).  The response 
rate was higher in the combination arm (24%) than in either single-agent arm (cisplatin:  
13%; bleomycin:  14%), although the difference was not statistically significant. 

Because of the higher response rate and significantly improved survival observed by 
Morton and colleagues with cisplatin therapy, a variety of antineoplastic agents were 
subsequently studied in combination with cisplatin in patients with advanced HNC.  
However, cisplatin combination chemotherapy has not shown statistically significant 
improvement in survival when compared to single-agent treatments (refer to Table 
JMHR.1), with median survival durations for single-agent cisplatin ranging from 5 to 8 
months. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Table JMHR.1. 

Reference 
Liverpool 
Head and Neck  
Oncology Group 
1990  

Jacobs et al. 1992  

Page 14 

Trials Evaluating Chemotherapy in Patients with Advanced 
HNC 

Study regimen 
(cid:127)  Cisplatin 100 mg/m 2 monthly 
(cid:127)  MTX 40 mg/m 2 biweekly 
(cid:127)  Cisplatin 100 mg/m 2 monthly + 5-FU 1000 mg/m2 

Survival 
Cis arm significantly 
better than MTX arm:  
p <0.025. 

for 4 days/month 

(cid:127)  Cisplatin 100 mg/m 2 + MTX 40 mg/m2, monthly 
(cid:127)  Cisplatin 100 mg/m 2 every 3 wks 
(cid:127)  5-FU 1000 mg/m 2 for 4 days every 3 wks 
(cid:127)  Cisplatin 100 mg/m 2 + 5-FU 1000 mg/m2 for 4 days 

every 3 wks 

No significant 
difference between 
arms: median OS of 5 
months for cis, 6.1 
months for 5-FU, and 
5.5 months for cis + 
5-FU.  
No significant 
difference between 
arms: median OS of 5.6 
months for MTX, 6.6 
months for cis + 5-FU, 
and 5 months for carbo 
+ 5-FU. 
No significant 
difference between 
arms: median OS of 
7.25 months for the 
entire group. 

No significant 
difference between 
treatment arms: median 
OS of 9.2 months for 
cetuximab + cis and 8.0 
months for cis + 
placebo. 

Forastiere et al. 1992  

(cid:127)  MTX 40 to 50 mg/m 2 weekly 
(cid:127)  Cisplatin 100 mg/m 2 Day 1 + 5-FU 1000 mg/m2 for 

4 days every 3 wks 

(cid:127)  Carboplatin 300 to 360 mg/m 2 Day 1 + 5-FU, every 

4 wks 

Clavel et al. 1994 

(cid:127)  MTX 40 mg/m 2 Days 1 and 5 + bleomycin 10 mg + 

vincristine 2 mg Days 1, 8, and 15 + cisplatin 
50 mg/m2 Day 4; every 3 wks 

(cid:127)  Cisplatin 100 mg/m 2 + 5-FU 1000 mg/m2 for 4 days 

every 3 wks 

(cid:127)  Cisplatin 50 mg/m 2 Days 1 and 8, every 4 wks 
(cid:127)  Cetuximab 200 mL/m 2 cycle 1, then 125 mL/m2/wk 

+ cisplatin 100 mg/m2 Day 1, every 4 wks 

(cid:127)  Placebo + cisplatin 100 mg/m 2 Day 1, every 4 wks 

Burtness et al. 2005 

Abbreviations:  carbo = carboplatin; cis = cisplatin; HNC = head and neck cancer; MTX = methotrexate; 

5-FU = 5-fluorouracil; OS = overall survival; wks = weeks. 

1.2.3.  Rationale for Use of Pemetrexed in Head and Neck 

Cancer 

1.2.3.1.  Mechanism of Action 
Pemetrexed is transported into cells by a reduced folate carrier and folate-binding protein 
(Theti and Jackman 2004).  Upon entry into the cell, pemetrexed undergoes 
polyglutamation by the action of the enzyme folylpolyglutamyl synthetase (Habeck et al. 
1995).  The polyglutamated metabolites of pemetrexed have prolonged intracellular 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 15 

retention times and are believed to play a profound role in determining the clinical 
antitumor activity of this novel agent. 

Studies have demonstrated that pemetrexed and its polyglutamate forms are potent 
competitive inhibitors of several key folate-requiring enzymes, including thymidylate 
synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide 
formyltransferase.  Inhibition of TS and DHFR is the primary mechanism of action of 2 
agents commonly used in the management of HNC patients:  5-FU and methotrexate.  
The polyglutamates of pemetrexed also inhibit other folate-requiring enzymes, such as 
aminoimidazole carboxamide ribonucleotide formyltransferase, C-1 tetrahydrofolate 
synthase, and C-1 tetrahydrofolate dehydrogenase.  The combined effects of the enzyme 
inhibition exerted by pemetrexed at each target give rise to an unusual end product 
reversal pattern and signature on metabolic folate and nucleotide pools, which are 
different from any other antifolates that have been studied so far (Shih et al. 1997).  Thus, 
pemetrexed represents a new class of antifolate cytotoxic agents with the promise of 
better overcoming inherent drug resistance through its multitargeted mechanism of 
action. 

1.2.3.2.  Development of Pemetrexed 

1.2.3.2.1.  Single-Agent Pemetrexed 
Early Phase 1 studies of pemetrexed without vitamin supplementation (conducted in 
patients with a variety of refractory solid malignancies) established the treatment 
schedule of pemetrexed administered once every 3 weeks.  The maximum-tolerated dose 
(MTD) for this regimen was 700 mg/m2, with dose-limiting toxicities (DLTs) of 
neutropenia, thrombocytopenia, and fatigue.  The dose selected for Phase 2 studies was 
600 mg/m2.  Later, to decrease the toxicity reported in the early Phase 2 studies, the 
recommended Phase 2 dose was decreased to 500 mg/m2, before the institution of routine 
folic acid and vitamin B12 administration.   

Based upon multivariate analyses of toxicities observed in several pemetrexed trials 
(Niyikiza et al. 2002), all patients receiving pemetrexed were subsequently supplemented 
with dietary folic acid (350 to 1000 µg) and vitamin B12 (1000 µg, administered as an 
intramuscular injection) to decrease the frequency of severe hematologic and 
nonhematologic toxicity.  Vitamin B12 was included in the supplementation because 
approximately 15% of patients were not expected to achieve lower homocysteine levels 
with the supplementation of daily folic acid alone.  It was hypothesized that these patients 
might benefit from the addition of vitamin B12 because this agent is a cofactor in the 
consumption of homocysteine by the methionine synthase enzyme. 

Folic acid and vitamin B12 supplementation caused a statistically significant reduction in 
plasma homocysteine concentrations over time and a significant reduction in the 
frequencies of severe hematologic toxicities and nonhematologic toxicities, such as 
mucositis, in patients receiving pemetrexed therapy (Bunn et al. 2001). 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 16 

The randomized Phase 3 trial, Study H3E-MC-JMEI (JMEI), confirmed the safety and 
tolerability of pemetrexed 500 mg/m2 with vitamin supplementation compared with 
docetaxel 75 mg/m2 in patients with locally advanced or metastatic non-small cell lung 
cancer (NSCLC) who were previously treated with chemotherapy.  Overall, Study JMEI 
showed that pemetrexed was as efficacious as docetaxel and had a more favorable safety 
profile.  The more favorable safety profile for pemetrexed was reflected in fewer 
clinically relevant toxicities, particularly neutropenia-related toxicities and associated 
supportive care (hospitalizations and concomitant medications), as well as fewer 
discontinuations and drug-related adverse events and serious adverse events (SAEs).  
Three study-drug-related deaths occurred on the pemetrexed arm, and 5 occurred on the 
docetaxel arm (Hanna et al. 2004). 

Pemetrexed is approved as second-line monotherapy for the treatment of patients with 
locally advanced or metastatic NSCLC in the United States (US) and in the European 
Union (EU). 

1.2.3.2.2.  Pemetrexed Plus Cisplatin 
Study H3E-MC-JMAP (JMAP) was a single-center, nonrandomized, open-label, Phase 1 
study of pemetrexed plus cisplatin without vitamin supplementation in patients with 
locally advanced or metastatic cancer to determine the MTD of pemetrexed and cisplatin 
administered in combination intravenously on a 21-day cycle.  No patients received 
low-dose folic acid or vitamin B12 because this study was completed before vitamin 
supplementation was implemented.  The primary cancers most frequently seen in these 
patients were mesothelioma (13 patients), HNC (11 patients), and non-small cell lung 
cancer (7 patients).  Seven patients (17%) had a performance status of 2.  Forty-five 
percent of the patients had received at least 1 prior chemotherapy regimen.  The MTD 
was pemetrexed 600 mg/m2 and cisplatin 100 mg/m2, because 2 of the 6 patients treated 
at this dose level experienced protocol-defined DLTs:  1 patient developed Grade 3 
mucositis and Grade 4 thrombocytopenia, and 1 patient experienced Grade 4 
thrombocytopenia.  At the next lower dose level (pemetrexed 600 mg/m2 and cisplatin 
75 mg/m2), only 1 of 13 patients had a protocol-defined DLT (Grade 3 neutropenia).  The 
data from this trial would have led to a dose of pemetrexed 600 mg/m2 and cisplatin 
75 mg/m2 being recommended for Phase 2 study.  However, because of toxicities 
observed in other single-agent Phase 2 studies, the recommended Phase 2 dose for this 
combination became pemetrexed 500 mg/m2 and cisplatin 75 mg/m2. 

The pivotal, randomized, Phase 3 trial, Study H3E-MC-JMCH (JMCH), established the 
safety and tolerability of the addition of pemetrexed 500 mg/m2 with vitamin 
supplementation to cisplatin 75 mg/m2, compared with single-agent cisplatin 75 mg/m2 
in patients with malignant pleural mesothelioma (MPM).  Few patients discontinued 
because of adverse events (12%).  Among patients who received vitamin 
supplementation, the drug-related death rate was low and similar between arms; all 
drug-related deaths in Study JMCH occurred in patients who did not receive vitamin 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 17 

supplementation.  The main toxicities of this regimen were hematologic (28% Grade 3 or 
4 neutropenia), but clinical manifestations of neutropenia, such as febrile neutropenia, 
were rare (<2%).  Grade 3 or 4 nonlaboratory toxicities, such as diarrhea and mucositis, 
which are common with other TS inhibitors, were observed in less than 5% of patients 
who received the pemetrexed plus cisplatin regimen.  Furthermore, the toxicity profile of 
the combination regimen of pemetrexed plus cisplatin was improved with folic acid and 
vitamin B12 supplementation.  Although the toxicity of pemetrexed in combination with 
cisplatin was higher than that of cisplatin alone, the increased toxicity was offset by the 
associated significant improvements in overall survival (OS), time to disease progression, 
response rate, pulmonary functioning, and pain in patients with MPM treated with 
pemetrexed and cisplatin (Vogelzang et al. 2003). 

Pemetrexed in combination with cisplatin is approved in the US and the EU for the 
treatment of patients with MPM whose disease is unresectable or who are otherwise not 
candidates for curative surgery. 

Study H3E-MC-JMDB (JMDB) was a multicenter, randomized, open-label, Phase 3 
study for first-line treatment of chemonaive patients with advanced/metastatic non-small 
cell lung cancer (NSCLC) with pemetrexed and cisplatin (PC) versus gemcitabine and 
cisplatin (GC).  The requirement for patient’s calculated creatinine clearance (CrCl) value 
in Study JMDB was ≥ 45 mL/min based on the standard Cockcroft and Gault formula 
(1976).  Of the 812 patients in PC arm who were randomized and treated at baseline, 65 
patients had CrCl of 45 to <60 mL/min  low CrCl group), and 747 had CrCl ≥ 60 mL/min 
(high CrCl group).  Clinically significant SAEs were similar between the low CrCl group 
and the high CrCl group, including renal toxicities.  When comparing all treatment-
emergent adverse events (TEAEs), the low CrCl group demonstrated more TEAEs 
involving renal toxicities, such as blood creatinine increase 10.8% versus 6% for high 
CrCl group, creatinine renal clearance decrease 26.2% versus 2%, and blood creatinine 
3.1% versus 0.54%.  Dose delays due to renal toxicities were also observed to be higher 
in the low CrCl group as compared to the high CrCl group, such as creatinine renal 
clearance decrease 10.8% versus 0.4% for high CrCl group.  All other reasons for dose 
delays were similar between the 2 groups.  Discontinuations due to SAEs and nonserious, 
clinically significant adverse event were 11 (16.9%) patients for the low CrCl group 
versus 57 (7.6%) patients for the high CrCl group; discontinuations for the low CrCl 
group were all related to renal events.  As expected, there were increased dose delays and 
discontinuations due to renal events in the low CrCl group.  However, most of the TEAEs 
observed in the low CrCl group were of Grade 1 or 2, and there was no increase in 
clinically significant SAEs.  Patients with CrCl of 45 to <60 mL/min did not exhibit 
significant increase in toxicity as compared to patients with CrCl ≥ 60 mL/min.  This is 
consistent with pemetrexed label to date.  Therefore, the calculated CrCl for Study JMHR 
patients will be ≥ 45 mL/min. 

Investigational sites involved in Study JMDB were also invited to participate in an 
optional companion biomarker research protocol.  Prospective analyses from the trial 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 18 

have been performed comparing OS and progression-free survival (PFS) by histologic 
type (squamous and nonsquamous NSCLC) (Scagliotti et al. 2007, 2008).  Statistically 
significant treatment-by-histology interactions were observed, with greater OS and PFS 
exhibited in patients treated with pemetrexed/cisplatin and having nonsquamous 
histology when compared to patients with squamous cell histology (Scagliotti et al. 2007, 
2008). 

Therefore, as part of Lilly’s ongoing efforts to understand the relationship between 
cancer, genetics, and response to therapy, Study JMHR will analyze biomarkers that will 
predict response to pemetrexed and cisplatin.  Study JMHR will also analyze the potential 
correlation between biomarkers and differences in underlying tumor cell type. 

1.2.3.3.  Development of Pemetrexed for Patients with Head and Neck 

Cancer 

1.2.3.3.1.  Single-Agent Pemetrexed for Patients with Head and Neck 

Cancer 

As a part of a broad Phase 2 program, pemetrexed was studied as a single agent in 
advanced HNC patients (Study H3E-MC-JMAJ [JMAJ]).  In this single-arm, Phase 2 
study of pemetrexed 500 mg/m2 without vitamin supplementation, a response rate of 
27% was observed in 36 patients with advanced HNC.  Approximately 30% of patients 
had received prior chemotherapy, and the majority had prior surgery and/or radiotherapy.  
Median PFS was 3.1 months, and median survival time was 6.4 months.  Toxicity was 
graded according to Common Toxicity Criteria (CTC) Version 1 (NCI 1993).  Grade 3/4 
neutropenia was reported for 65% of patients, and Grade 4 thrombocytopenia was 
observed in 11.4%.  Grade 3/4 infection was observed in 17.1% of patients.  Four deaths 
were attributed to toxicity from study treatment (asphyxia secondary to laryngeal 
hemorrhage, septic shock, septicemia, as well as laryngeal tumor bleeding and dyspnea). 

1.2.3.3.2.  Pemetrexed Plus Cisplatin for Patients with Head and Neck 

Cancer 

In Study JMAP (see Section 1.2.3.2.2), 3 of the 11 patients with locally advanced or 
metastatic HNC were observed to have a partial response to study treatment. 

1.2.3.4.  Summary and Conclusions 
Thus, the rationale for the development of pemetrexed in combination with cisplatin in 
advanced HNC is as follows: 

•  Because no platinum-based combination has improved survival in patients 

with advanced HNC compared with single-agent cisplatin, there is a 
significant unmet medical need in this patient population. 

•  Phase 2 data established the activity of single-agent pemetrexed 

500 mg/m2 without vitamin supplementation in advanced HNC patients. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 19 

•  The addition of vitamin supplementation to pemetrexed treatment led to a 

manageable and predictable toxicity profile for pemetrexed and for 
pemetrexed plus cisplatin. 

•  Pemetrexed with vitamin supplementation plus cisplatin showed 

significant improvements in OS, with acceptable toxicity, compared with 
single-agent cisplatin in Study JMCH, a randomized, Phase 3 trial that led 
to the global registration of pemetrexed plus cisplatin combination therapy 
in patients with MPM. 

•  Experience gained with pemetrexed in a variety of tumors, including 

HNC, provides evidence that pemetrexed in combination with cisplatin 
with vitamin supplementation can be safely administered in this patient 
population. 

•  Pemetrexed, either as a single agent or in combination with cisplatin, has 

shown promising activity in patients with advanced HNC. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 20 

2.  Objectives 

2.1.  Primary Objective 
The primary objective of this study is to compare the OS of pemetrexed 500 mg/m2 plus 
cisplatin 75 mg/m2 every 3 weeks to the OS of single-agent cisplatin 75 mg/m2 every 3 
weeks in patients with HNC that is recurrent and not amenable to local therapy (surgery 
or radiation) or newly diagnosed distant metastatic disease. 

2.2.  Secondary Objectives 
The secondary objectives of this study are to compare between the two treatment arms: 

•  progression-free survival (PFS) 
•  overall response rate (ORR) 
•  duration of response (DoR) for responding patients 
• 

time to worsening (TTW) in dimensions of health-related quality of life 
(HRQoL) using Functional Assessment of Cancer Therapy - Head and 
Neck Cancer (FACT-H&N) 

•  change from baseline in dimensions of HRQoL using FACT-H&N 
• 

the safety and adverse event profile (including Common Terminology 
Criteria for Adverse Events [CTCAE Version 3.0, NCI 2003] grades for 
laboratory and nonlaboratory adverse events) 

• 

to assess the ability of biological markers relevant to study therapy and 
disease state to identify difference in treatment effect on overall survival 
and on other relevant clinical endpoints including PFS, tumor response, 
and toxicity. 

Definitions for efficacy, HRQoL, and safety measures can be found in Sections 6.1, 6.2, 
and 6.3, respectively. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version 3. 

Investigational Plan 

Page 21 

3.1.  Summary of Study Design 
Study H3E-MC-JMHR (JMHR) is a double-blind, randomized, Phase 3 study in patients 
with HNC that is recurrent and not amenable to local therapy (surgery or radiation) or 
newly diagnosed distant metastatic disease.  Approximately 790 patients will be enrolled 
in this study.  Eligible patients will be randomized to one of the following treatment 
arms: 

•  Arm A (experimental arm):  pemetrexed 500 mg/m2 plus cisplatin 

75 mg/m2 on Day 1 every 21 days 

•  Arm B (control arm):  placebo plus cisplatin 75 mg/m2 on Day 1 every 21 

days 

Patients in both treatment arms will receive up to 6 cycles of assigned study treatment 
and will also receive folic acid, vitamin B12 supplementation  and dexamethasone (refer 
to Section 5.2.4 through Section 5.2.6).  All patients will be followed until death or study 
closure.  However, a patient who is receiving benefit from treatment may receive 
additional cycles after discussion between the El  Lilly and Company (Lilly) physician 
and the investigator.  In this case, cycles will be repeated until the patient meets the 
criteria for study treatment discontinuation (Section 4.3). 

Patients will be evenly assigned (1:1 randomization) to the treatment arms based on the 
following randomization factors:  Eastern Cooperative Oncology Group (ECOG) 
performance status (0 or 1 versus 2), previously treated for HNC (no versus yes), distant 
metastasis (no versus yes), prior platinum-based therapy (no versus yes), and country. 

The primary efficacy measure will be OS.  Secondary endpoints include PFS, ORR, and 
DoR; time to worsening (TTW) in dimensions of health-related quality of life (HRQoL) 
using FACT-H&N, change from baseline in dimensions of HRQoL using FACT-H&N, 
and safety.  The study is powered to detect a 25% improvement in OS when pemetrexed 
is combined with cisplatin by showing the median OS of 8 months with cisplatin plus 
placebo and 10 months with pemetrexed plus cisplatin. The 8-month survival estimate for 
cisplatin plus placebo is based on results from the Burtness trial (see Table JMHR.1). 

After approximately 632 deaths have been observed, the database for the final analysis 
will be validated and “locked” for the final analysis and preparation of the clinical study 
report. 

An interim analysis for futility is planned for this study. The interim analysis will be 
performed to assess safety and efficacy in order to determine whether it is scientifically 
and ethically appropriate to continue enrollment.  The futility analysis will be based on 
PFS as the OS data is not anticipated to mature at the time of interim analysis.  The 
interim analysis will be conducted when approximately 300 patients have experienced 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version disease progression or have died.  Patient enrollment will continue during the interim 
analysis.  (See Section 8.2.11 regarding details about the interim analysis and about 
formation of the data monitoring board.) 

Figure JMHR.1 illustrates the study design. 

Page 22 

 

 

Screening

Randomization

Pretreatment – Both Treatment Arms
Dexamethasone (po): 4 mg BID taken on the day before, the day of, and day after study 
treatment.
Vitamin B12 (im): 1000 µg taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks 
after last treatment dose.
Folic Acid (po): 350 µg to 1000 µg taken 1 to 2 weeks before treatment and continue daily until 3
weeks after last treatment dose.

Treatment Arm A

Pemetrexed 500 mg/m2 + cisplatin 75 mg/m2

on Day 1 every 21 days

Treatment Arm B
Placebo + cisplatin 75 mg/m2

on Day 1 every 21 days

Patients will receive up to 6 cycles of therapy.

All patients will be followed until death or end of study.

 

Abbreviations:  BID = twice daily; im = intramuscularly; po = oral. 

Figure JMHR.1. 

Illustration of H3E-MC-JMHR study design. 

3.2.  Discussion of Design and Control 
Approximately 790 patients will be randomized to receive either pemetrexed plus 
cisplatin (Treatment Arm A) or placebo plus cisplatin (Treatment Arm B) in a 1:1 manner 
(395 patients in Treatment Arm A and 395 patients in Treatment Arm B).  A double-blind 
design has been chosen for Study JMHR to minimize investigator and patient bias with 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version respect to treatment decisions and patient-reported outcomes.  Because OS is the primary 
endpoint of this double-blind study, no independent review of PFS or ORR is planned.  
The sponsor will collect and store all tumor measurement images on all patients 
throughout the study. 

Page 23 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version 4.  Study Population 

Page 24 

Inclusion Criteria 

4.1. 
Patients are eligible to be included in the study only if they meet all of the following 
criteria: 

[1]  Histologic or cytologic diagnosis of squamous cell HNC, either: 

• 

Recurrent disease (locally advanced or metastatic) that is not 
amenable to local therapy, (i) with at least 6 months since 
completion of systemic therapy (chemotherapy or biological 
anticancer therapy), and (ii) with no more than 1 prior 
multimodal therapy (such as concurrent chemoradiation with or 
without sequential chemotherapy) for locally advanced HNC 
tumor, and (iii) with no prior systemic therapy (chemotherapy or 
biological anticancer therapy) for metastatic disease; OR 
•  Newly diagnosed distant metastatic disease (Stage IVc). 

[2]  Prior therapies: 

•  Radiation therapy must be completed at least 4 weeks before study 
enrollment.  For palliative therapy, prior radiation therapy allowed 
to <25% of the bone marrow (Cristy and Eckerman 1987), and 
prior radiation to the whole pelvis is not allowed.  Patients must 
have recovered from the acute toxic effects of the treatment prior 
to study enrollment. 

•  Surgery (excluding prior diagnostic biopsy) must be completed at 

least 4 weeks before study enrollment.  Patients must have fully 
recovered from any acute effects of surgery prior to study 
enrollment. 

[3]  Life expectancy ≥3 months. 
[4]  Eastern Cooperative Oncology Group (ECOG) performance status 0, 

1, or 2 (Oken et al. 1982).  See Protocol Attachment JMHR.3. 

[5]  Disease status may be measurable or nonmeasurable as defined by 

Response Evaluation Criteria in Solid Tumors (RECIST; Therasse et 
al. 2000).  Positron emission tomography (PET) scans and ultrasounds 
may not be used for lesion measurements. 

[6]  Patient compliance and geographic proximity that allow for adequate 

follow-up. 

[7]  Adequate organ function as defined by the following: 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 25 

• 

Bone marrow reserve:  absolute neutrophil (segmented and 
bands) count (ANC) ≥1.5 × 109/L, platelets ≥100 × 109/L, and 
hemoglobin ≥9 g/dL. 

•  Hepatic:  bilirubin ≤1.5 × the upper limit of normal (ULN); 

alkaline phosphatase (ALP), aspartate aminotransferase (AST), 
and alanine aminotransferase (ALT) ≤3.0 × ULN.  (ALP, AST, 
and ALT ≤5.0 × ULN is acceptable if the liver has tumor 
involvement.) 
Renal:  calculated creatinine clearance (CrCl) ≥ 45 mL/min.  (See 
Section 5.5.2.3 and Protocol Attachment JMHR.4 for acceptable 
methods of creatinine clearance assay.) 

• 

[8]  Signed informed consent from patient. 

[9]  Patients at least 18 years of age. 

[10]  For women:  Must be surgically sterile, postmenopausal, or compliant 

with a medically approved contraceptive regimen (for example, 
intrauterine device [IUD], birth control pills, or barrier device) during 
and for 6 months after the treatment period; must have a negative 
serum or urine pregnancy test within 7 days before study enrollment, 
and must not be breast-feeding. 

For men:  Must be surgically sterile or compliant with a contraceptive 
regimen during and for 6 months after the treatment period. 

4.2.  Exclusion Criteria 
Patients will be excluded from the study if they meet any of the following criteria: 

[11]  Prior systemic therapy (chemotherapy or biological anticancer 

therapy) for metastatic disease. 

[12]  Have received treatment within the last 30 days with a drug that has 

not received regulatory approval for any indication at the time of study 
entry. 

[13]  Serious concomitant systemic disorder (for example active infection or 

cardiac disease) or psychiatric disorder that, in the opinion of the 
investigator, would compromise the patient’s ability to complete the 
study. 

[14]  Presence of clinically significant (by physical exam) third-space fluid 

collections, for example, ascites or pleural effusions that cannot be 
controlled by drainage or other procedures prior to study entry. 

[15]  Second primary malignancy that is clinically detectable at the time of 

consideration for study enrollment. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 26 

[16]  Have had another primary malignancy other than HNC, unless that 

prior malignancy was treated at least 2 years previously with no 
evidence of recurrence.  Exception:  Patients with a history of in situ 
carcinoma of the cervix, nonmelanoma skin cancer, or low-grade 
(Gleason score ≤6) localized prostate cancer will be eligible even if 
diagnosed and treated less than 2 years previously.   

[17]  Nasopharyngeal, paranasal sinus, lip, or salivary gland cancer. 

[18]  Have central nervous system (CNS) metastases (unless the patient has 
completed successful local therapy for CNS metastases and has been 
off corticosteroids for at least 4 weeks before starting study therapy).  
Brain imaging is required in symptomatic patients to rule out brain 
metastases, but is not required in asymptomatic patients. 

[19]  Inability to interrupt aspirin or other nonsteroidal anti-inflammatory 

agents, other than an aspirin dose ≤1.3 grams per day, for a 5-day 
period (8-day period for long-acting agents, such as piroxicam). 

[20]  Unable or unwilling to take folic acid, vitamin B12, or prophylactic 

corticosteroids. 

[21]  Concurrent administration of any other antitumor therapy. 

[22]  Pregnant or breast-feeding. 

4.2.1.  Rationale for Exclusion of Certain Study Candidates 
Exclusion Criterion [12] uses the 30-day standard established by Lilly in order to clearly 
attribute events associated with an investigational agent with the appropriate 
investigational agent.  Exclusion Criteria [11], [13], [14], [15], [16], [17], and [18] help to 
establish specificity of the patient population for both efficacy and safety analyses.  
Exclusion Criteria [19], [20], and [21] provide for patient safety.  Because preclinical 
data suggest that pemetrexed may have teratogenic effects, and safety has not been 
established for nursing infants, Exclusion Criterion [22] ensures patient safety.   

4.3.  Discontinuations 
The criteria for enrollment must be followed explicitly.  If a patient who does not meet 
enrollment criteria is inadvertently enrolled, that patient should be discontinued from the 
study treatment, and Lilly or its designee must be contacted.  An exception may be 
granted in rare circumstances where the patient has a serious or life-threatening condition 
for which there is no effective alternative therapy and, in the opinion of the investigator, 
is receiving benefit from study treatment.  In these rare cases, the investigator must obtain 
documented approval from Lilly to allow the patient to continue study treatment.  In 
addition, patients will be discontinued from study treatment in the following 
circumstances: 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 27 

•  The investigator decides that the patient should be withdrawn from the 
study treatment.  If an SAE or a clinically significant laboratory value is 
the basis for this decision, the investigator will discontinue the study 
treatment, take appropriate measures, and immediately notify Lilly or its 
designee (see Safety, Section 6.3). 

•  The patient experiences any unacceptable adverse event that would require 

a third dose reduction. 

•  The patient or the attending physician requests that the patient be 

withdrawn from the study treatment. 

•  The patient cannot receive study treatment for 42 or more consecutive 

days from the first day of the previous cycle for any reason. 

•  The patient, for any reason, requires treatment with another therapeutic 
agent for this study indication.  In this case, discontinuation from study 
treatment occurs immediately upon introduction of the new agent. 

•  The investigator or Lilly, for any reason, stops the study or stops the 

patient's participation in the study. 

•  The patient has completed 6 cycles of study treatment. 
•  There is evidence of progressive disease (PD). 
•  The patient becomes pregnant or fails to use adequate birth control. 
•  The patient is noncompliant with study procedures. 

The date a patient discontinues study treatment will also be the first day of the patient’s 
30-day postdiscontinuation follow-up visit (refer to the Study Schedule in Protocol 
Attachment JMHR.1). 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 28 

5.  Treatment 

5.1.  Treatments Administered 
This study will randomize patients to receive pemetrexed plus cisplatin or placebo plus 
cisplatin, as follows: 

  Arm A (experimental arm):  pemetrexed 500 mg/m2 plus cisplatin 

75 mg/m2 on Day 1 every 21 days 

  Arm B (control arm):  placebo (approximately 100 mL normal saline) 

plus cisplatin 75 mg/m2 on Day 1 every 21 days 

Table JMHR.2 (see Section 5.5) outlines the details of each treatment regimen, including 
supportive therapies. 

The investigator or his/her designee is responsible for explaining the correct use of the 
investigational agent(s) to the site personnel, verifying that instructions are followed 
properly, maintaining accurate records of study drug dispensing and collection, and 
returning all unused medication to Lilly at the end of the study. 

Patients will be instructed to contact the inves igator as soon as possible if he or she has a 
complaint or problem with the study drug so that the situation can be assessed. 

5.2.  Materials and Supplies 
Clinical trial materials will be labeled according to the country’s regulatory requirements.   

5.2.1.  Pemetrexed (Treatment Arm A) 
The freeze-dried drug product contains pemetrexed disodium and mannitol in a 1:1 ratio.  
Sodium hydroxide  hydrochloric acid solution, or both, may be added during processing 
to adjust the pH.  The 500-mg vial contains pemetrexed disodium equivalent to 510 mg 
of the base compound, pemetrexed.  The vials contain a 2% excess to facilitate the 
withdrawal of the label amount from the vial.  The drug product is stable when stored at 
controlled room temperature. 

Reconstituting the 500-mg vial contents with 10 to 50 mL of sodium chloride injection 
gives a clear solution with a concentration of 10 to 50 mg/mL.  The reconstituted 
formulation is in the pH range of 6.8 to 7.5 and is chemically stable for 72 hours at 
refrigerated or room temperature.  However, the drug product contains no antimicrobial 
agent and should be administered within 24 hours after reconstitution in the original vial.  
Investigative site staff should discard unused portions.  Responsible individuals should 
inspect vial contents for particulate matter before and after they withdraw the drug 
product from a vial into a syringe. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 29 

Investigative site personnel cannot administer the concentrated solution without further 
dilution.  For the purposes of clinical administration, site staff must dilute an appropriate 
quantity of the reconstituted contents of the vial into an infusion solution of 
approximately 100 mL of 0.9% sodium chloride for injection.  After dilution, the shelf 
life of the product is 24 hours at room temperature.  Pemetrexed is not sensitive to light.  
Vials of pemetrexed contain no antimicrobial preservative, and they are single-use vials.  
Site staff must not store any unused portion of a vial for future use and they must discard 
unused portions of product. 

Pemetrexed is incompatible in solution with acidic medications or media, and site staff 
must not mix or administer simultaneously with other medications through the same 
infusion line.  Site personnel should flush the infusion line before administration of any 
concomitant medication.  Pemetrexed is compatible with standard polyvinyl chloride 
administration sets and intravenous solution bags. 

Site staff should inspect parenteral drug products visually for particulate matter and 
discoloration before administration whenever solution and container permit inspection. 

5.2.2.  Cisplatin (Both Treatment Arms) 
Cisplatin will be obtained locally.  A total dose of 75 mg/m2 of cisplatin will be diluted to 
a volume of 1000 mL with 0.9% sodium chloride prior to infusion.  The cisplatin solution 
should not be refrigerated.  Prior to and following the administration of cisplatin, the 
patient will be adequately hydrated according to local practice. 

5.2.3.  Placebo (Treatment Arm B)  
Placebo is normal saline (0.9% sodium chloride), and normal saline will also serve as the 
diluent for pemetrexed and cisplatin (Sections 5.2.1 and 5.2.2). 

Patients who are assigned to Treatment Arm B will receive approximately 100 mL 
normal saline in place of the pemetrexed infusion.  In order to protect the blinding of the 
study, the IV bags containing normal saline either with or without pemetrexed should be 
visually indistinguishable for Treatment Arms A and B.  (Refer to Section 5.6, Blinding.) 

5.2.4.  Folic Acid (Both Treatment Arms) 
Investigators will obtain folic acid as one of the following options, with preference in 
order from Option 1 to Option 3: 

1) 

2) 

3) 

350 to 600 µg folic acid 
a multivitamin containing folic acid in the range of 350 to 600 µg 
(acceptable only if Option 1 is not available) 
a dose of folic acid between 600 and 1000 µg (acceptable only if 
neither Option 1 nor Option 2 is available). 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 30 

For purposes of this study, all patients should take oral folic acid daily beginning 
approximately 1 to 2 weeks before treatment with pemetrexed plus cisplatin or cisplatin 
alone and continuing daily until 3 weeks after discontinuation from study therapy. 

5.2.5.  Vitamin B12 (Both Treatment Arms)  
Vitamin B12 will be prescribed by the investigator and administered as a 1000-µg 
intramuscular injection.  A vitamin B12 injection must be administered approximately 1 
to 2 weeks before treatment with pemetrexed plus cisplatin or cisplatin alone and should 
be repeated approximately every 9 weeks until 3 weeks after the last dose of study 
treatment. 

5.2.6.  Dexamethasone (Both Treatment Arms) 
Dexamethasone is one of a variety of corticosteroids available in tablet form ranging 
from 0.25 to 6 mg.  For purposes of this study, all patients will be given dexamethasone 
4 mg orally (or an equivalent corticosteroid and dose) twice per day on the day before, 
the day of, and the day after each dose of pemetrexed plus cisplatin or cisplatin alone. 

5.3.  Method of Assignment to Treatment 
A computerized, interactive, voice-activated response system (IVRS) at a central location 
will control random assignment for all study sites.  In order to preserve the blinding of 
the patient and the personnel involved in patient evaluations or data collection, an 
unblinded third party (for example, a pharmacist) will be designated.  The investigator 
should provide the necessary information to the unblinded pharmacist or designee who 
will call the IVRS to obtain the patient’s treatment assignment.  Neither the patient nor 
the investigator will know the treatment to which the patient has been assigned. 

The IVRS will assign patients to treatment arms according to the method of Pocock and 
Simon (1975).  Each patient will be assigned with probability 0.75 to the treatment arm 
that minimizes imbalances among the following equally weighted prognostic factors.  If 
the measures of imbalance are equal for both arms, then the probability of allocation to 
either arm will be 0.5.  Prognostic factors considered by the randomization algorithm are: 

•  ECOG Performance Status: 
○  Baseline score = 0 or 1 

○  Baseline score = 2 

•  Previously treated for HNC: 

○  No 

○  Yes 

•  Distant metastasis: 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 31 

○  No 

○  Yes 

•  Prior platinum-based therapy: 

○  No 

○  Yes 
•  Country 

5.4.  Rationale for Selection of Doses in the Study 

5.4.1.  Cisplatin 
In randomized clinical trials in advanced HNC patients, cisplatin is frequently dosed at 
75  mg/m2 every 3 weeks or 100 mg/m2 every 3 or 4 weeks, either as a single agent or as 
combination therapy (yielding a planned cisplatin dose intensity of 25 to 33 mg/m2/wk).  
In the Morton trial, in which a survival advantage was reported for cisplatin-based 
regimens over best supportive care, the planned cisplatin dose intensity was 25 
mg/m2/wk in both the cisplatin-only arm and the cisplatin-bleomycin arm (Morton et al. 
1985).  In the Clavel study, the planned dose intensity was 25 mg/m2/wk for cisplatin 
monotherapy, 33 mg/m2/wk for cisplatin plus 5-FU, and 16 mg/m2/wk for the cisplatin 
plus methotrexate plus bleomycin plus vincristine regimen; the Clavel study did not show 
a statistically significant difference in OS between arms (Clavel et al. 1994).  Together, 
cisplatin-based trials in advanced HNC patients suggest that efficacy does not vary 
substantially based on cisplatin dose intensity.  Veronesi and colleagues did not report 
significant differences in response rate, PFS, or OS in advanced HNC patients treated 
with either cisplatin 60 mg/m2 every 3 wks (20 mg/m2/wk) or cisplatin 120 mg/m2 every 
3 wks (40 mg/m2/wk), suggesting that cisplatin activity has limited drug-dose 
dependency in patients with advanced HNC (Veronesi et al. 1985).  Lastly, single-agent 
cisplatin 25 mg/m2/wk has shown similar efficacy to other cisplatin combination 
chemotherapies. 

Therefore, the proposed dosage for cisplatin in Study JMHR for both the comparator arm 
and the experimental arm is 75 mg/m2 administered intravenously every 3 weeks to yield 
a planned dose intensity of 25 mg/m2/wk. 

5.4.2.  Pemetrexed in Combination with Cisplatin 
As mentioned in Section 1.2.3.3.1, single-agent pemetrexed 500 mg/m2 without vitamin 
supplementation showed promising activity in locally advanced or metastatic HNC in 
Study JMAJ. 

In Study JMAP (see Section 1.2.3.2.2), a toxic death was reported in 1 HNC patient 
treated with pemetrexed 600 mg/m2 and cisplatin 75 mg/m2 without vitamin 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 32 

supplementation.  The patient experienced multiple CTC Grade 3 and 4 toxicities during 
Cycle 1 of therapy:  stomatitis, dysphagia, neutropenia, thrombocytopenia, and sepsis 
with pneumonia.  The patient died on Day 16.  Cause of death was not determined; an 
autopsy was performed. 

In Study JMCH (see Section 1.2.3.2.2), cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2 
showed a manageable safety profile when administered with vitamin supplementation in 
the treatment of patients with MPM and led to its approval in the treatment of this cancer. 

Therefore, the proposed experimental treatment in Study JMHR is cisplatin 75 mg/m2 
plus pemetrexed 500 mg/m2 with vitamin supplementation, both agents administered on 
Day 1 of a 3-week schedule. 

5.5.  Selection and Timing of Doses 
A delay of cycle as a result of holidays, weekends, bad weather, or other unforeseen 
circumstances will be permitted and not counted as a protocol violation. 

For patients on Treatment Arm A, the definition of a cycle is 1 dose of pemetrexed plus 1 
dose of cisplatin administered on Day 1 every 21 days. 

For patients on Treatment Arm B, the definition of a cycle is placebo (saline infusion) 
plus 1 dose of cisplatin administered on Day 1 every 21 days. 

The site will determine the actual doses of  he drugs to be administered to patients on 
both treatment arms by calculating the patient’s body surface area at the beginning of 
each cycle.  

Table JMHR.2 describes the dosage and the mode of administration for each study 
therapy. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Table JMHR.2. 

Dosages and Mode of Administration of Study Therapies 

Page 33 

Dose 

Time of Administration 

Drug 
Treatment Arm A (21-Day Cycle) 
Pemetrexed 
Cisplatin 

500 mg/m2 iv infusion 
75 mg/m2 iv infusion 

Approximately 10 minutes on Day 1. 
Hydration to be administered per local 
practice on Day 1. 

Treatment Arm B (21-Day Cycle) 
Saline infusion as placebo  Approximately 100 mL iv 

Approximately 10 minutes on Day 1.  

Cisplatin 

infusion 
75 mg/m2 iv infusion 

Pretreatment–Both Treatment Arms A and B 
Folic acid 

350 µg to 1000 µg orally 

Vitamin B12 

1000 µg im injection 

Dexamethasone 

4 mg, orally twice per day 
(or equivalent) 

Hydration to be administered per local 
practice on Day 1. 

Dose daily, beginning approximately 1 to 
2 weeks before the first dose of study 
therapy, and continuing daily until 3 weeks 
after the last dose of study therapy.  
Section 5.5 2.5 defines sufficient folic acid 
supplementation. 
Approximately 1 to 2 weeks before the first 
dose of study therapy, and approximately 
every 9 weeks until 3 weeks after the last 
dose of study therapy.  Section 5.5.2.5 
defines sufficient vitamin B12 
supplementation. 
Should be taken on the day before, the day 
of, and the day after each dose of study 
therapy.  Higher or additional doses are 
permitted for reasons other than routine rash 
prophylaxis (for example, antiemetic 
prophylaxis). 

Abbreviations:  im = intramuscular; iv = intravenous. 

5.5.1.  Special Treatment Considerations 
To maintain blinding of the study, patients in Treatment Arm B will receive 
approximately 100 mL normal saline in place of pemetrexed infusion.  The IV bags 
containing normal saline either with or without pemetrexed should be visually 
indistinguishable for Treatment Arms A and B (see Section 5.6, Blinding).  All patients 
will receive vitamin supplementation and prophylactic corticosteroids irrespective of 
treatment assignment. 

5.5.2.  Dose Adjustments or Delays for Subsequent Cycles 
Any patient who requires a dose reduction of pemetrexed or cisplatin will continue to 
receive the reduced dose for the remainder of the study.  Any patient who has 2 dose 
reductions and experiences an adverse event that would require a third dose reduction 
must be discontinued from study treatment. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 34 

Treatment may be delayed for up to 42 days to allow a patient sufficient time for 
recovery from a study-drug-related adverse event.  A patient who cannot be administered 
study drug for 42 days from the time of last treatment must be discontinued from study 
treatment. 

5.5.2.1.  Hematologic Adverse Events 
Dose adjustments at the start of a subsequent cycle of study treatment will be based on 
nadir (lowest value) platelet and absolute neutrophil counts from the preceding cycle.  
Prior to treatment, the ANC must be ≥1.5 × 109/L, and platelets must be ≥100 × 109/L.  
Treatment should be delayed to allow sufficient time for recovery.  Upon recovery, 
treatment should be administered according to the guidelines in Table JMHR.3 below. 

Table JMHR.3. 

Dose Adjustments for Pemetrexed/Cisplatin or Cisplatin 
Based on Nadir Hematologic Values Prior to Next Dose  

 
Platelets (× 109/L) 
 
≥50 
≥50 
<50 
<50 with bleeding  
Any 
Recurrence of CTCAE 
Grade 3 or 4 after two dose 
reductions 

 

 

and 
and 
and 
and 
and 
or 

 

ANC (× 109/L) 

Percentage of Previous 

Dose (Both Drugs) 

 

≥0.5 
<0.5 
Any 
Any 

<1.0 + fever of ≥38.5°C    

 

100% 
75% 
75% 
50% 
75% 

Recurrence of CTCAE Grade 3 
or 4 after two dose reductions 

Discontinue from 
study treatment 

Abbreviations:  ANC = absolute neutrophil count; CTCAE = Common Terminology Criteria for Adverse 

Events (Version 3.0; NCI 2003). 

 

5.5.2.2.  Nonhematologic Adverse Events 
In general, for nonhematologic adverse events greater than or equal to CTCAE Grade 3, 
treatment should be delayed until resolution to less than or equal to the patient’s baseline 
value before resuming treatment.  Dose reductions at the start of the subsequent cycle 
will be based on nonhematologic adverse events from the dose administered in the 
preceding cycle. 

Table JMHR.4 provides the relevant dose adjustments of pemetrexed and cisplatin for 
nonhematologic adverse events. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 35 

Table JMHR.4. 

Dose Adjustments for Pemetrexed or Cisplatin 
Nonhematologic Adverse Events 
Prior to the Next Dose 

 
CTCAE Grade 
G4 nausea or vomiting 
G3 aminotransferase elevations 
G4 aminotransferase elevations 

G3 or G4 mucositis 
G3 or G4 diarrhea  
   (or any grade requiring hospitalization) 
Other G3 or G4 nonhematologic 
CTCAEsa 
Recurrence of G3 or G4 CTCAE after 
two dose reductions 

Percent of Previous Dose 

Dose for Pemetrexed 

Dose for Cisplatin 

75% 
75% 

75% 
75% 

Discontinue from 
study treatment 

Discontinue from 
study treatment 

50% 

75% 

75% 

100% 

75% 

75% 

Discontinue from 
study treatment 

Discontinue from 
study treatment 

Abbreviations:  CTCAE = Common Terminology Criteria for Adverse Events (Version 3; NCI 2003); G3 = 

Grade 3; G4 = Grade 4 

a  If deemed appropriate by the treating physician. 
 

5.5.2.3.  Creatinine Clearance 
Creatinine clearance calculation will be based on the standard Cockcroft and Gault 
formula (1976) or on measured glomerular filtration rate (GFR) as assayed by a 24-hour 
urine sample or the appropriate radiolabeled method (51-CrEDTA or Tc99m-DTPA).  
The method of CrCl assessment that is used at baseline should be used throughout the 
study.  Enrollment and dosing decisions based on CrCl values may be made using either 
local lab values (calculated using the acceptable assay methods [Protocol Attachment 
JMHR.4]) or central laboratory values. 

If the local CrCl value is used for enrollment and dosing decisions for a patient, the 
serum creatinine must be assayed at the same local lab each time for that patient.  If a 
local lab is being used to monitor a patient’s renal function, the central laboratory sample 
still must be drawn for safety analysis. 

Prior to study treatment (at baseline), creatinine clearance should be ≥ 45 mL/min.  At 
subsequent cycles, if a patient’s CrCl value is <45 mL/min, the pemetrexed and cisplatin 
doses should be delayed to allow the patient to recover from toxicity.  Table JMHR.5 
provides the relevant dose adjustments of pemetrexed and cisplatin according to value of 
creatinine clearance. 

If the patient’s CrCl value has not returned to ≥ 45 mL/min within 42 days of the last 
doses of pemetrexed and cisplatin administration, the patient must be discontinued from 
study treatment unless continuation is approved by the Lilly clinical research physician 
(CRP).  Safety analysis will be based on the central laboratory serum creatinine and 
calculated CrCl values. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 36 

Table JMHR.5. 

Dose Adjustments for Creatinine Clearance 

 
CrCl Value  
≥45 mL/min 
<45 mL/min 

Percent of Previous Dose 

Dose for Pemetrexed 

Dose for Cisplatin 

100% 

Dose delay a 

100% 

Dose delay a 

Abbreviation:  CrCl = creatinine clearance. 
a  Delay treatment for up to 2 cycles (42 days).  If, after 42 days of the last doses of administration, the 

patient’s creatinine clearance remains <45 mL/min, discontinued patient from study treatment. 

5.5.2.4.  Dose Adjustments for Neurosensory Adverse Events 
Table JMHR.6 documents the relevant dose adjustments in case of neurosensory adverse 
events. 

Table JMHR.6. 

Dose Adjustments for Neurosensory Adverse Events 

 
CTCAE Grade 
0 to 1  
2 

3 to 4 

Percent of Previous Dose 

Dose for Pemetrexed 

Dose for Cisplatin 

100% 
100% 

Discontinue from 
study treatment 

100% 
50% 

Discontinue from 
study treatment 

Abbreviation:  CTCAE = Common Terminology Criteria for Adverse Events (NCI 2003). 
 

5.5.2.5.  Treatment Delays Due to Insufficient Folic Acid or Vitamin B12 

Supplementation 

The first dose of study drug should be delayed until the patient has taken folic acid for at 
least 5 of the 7 days before Day 1 of Cycle 1 and until the vitamin B12 injection has been 
administered.  Subsequent doses should be delayed until the patient has taken folic acid 
for at least 14 of the 21 days before Day 1 of the cycle. 

5.6.  Blinding 
Study JMHR is a randomized, double-blind study.  Treatment Arm A is defined as 
pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2, both administered intravenously on 
Day 1 of a 21-day cycle.  Treatment Arm B is defined as placebo plus cisplatin 
75 mg/m2, both administered intravenously on Day 1 of a 21-day cycle.  In order to 
maintain blinding of the study, patients randomized to Treatment Arm B will receive 
approximately 100 mL of normal saline in place of pemetrexed infusion.  Infusion bags 
containing saline with or without pemetrexed should be visually indistinguishable for 
Treatment Arms A and B.  The unblinded pharmacist or designee at each site will prepare 
the study drugs. 

If, in the investigator’s opinion, knowledge of treatment assignment would alter 
management of SAEs, the investigator or designee may be unblinded through the IVRS 
to obtain the patient treatment assignment.  This option may be used only if the patient's 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 37 

well-being requires that medical staff have knowledge of the patient’s treatment 
assignment.  All calls resulting in an unblinding event are recorded and reported by the 
IVRS.  If the IVRS is inoperable, the investigator or designee must contact the unblinded 
pharmacist to obtain the patient’s treatment assignment. 

The investigator should make every effort to contact the Lilly CRP prior to unblinding a 
patient's treatment assignment.  If a patient’s treatment assignment is unblinded, Lilly 
must be notified immediately by telephone.  The investigator or designee must document 
any unblinding event, and this documentation will include the patient’s number, the date, 
and the reason for unblinding. 

While every effort will be made to blind both the patient and the investigator to the 
identity of the treatment, the inadvertent unblinding of a patient may occur.  This 
unblinding will not be sufficient cause (in and of itself) for that patient to be discontinued 
from the study treatment or excluded from any safety or efficacy analysis. 

Efficacy information will not be shared between sites until the study is completed.  
Treatment assignment will be scrambled in the reporting database until database lock for 
data analysis.  This will ensure unblinded aggregate efficacy results are not available until 
the time of the data analysis.  There is a planned interim analysis for futility.  Only the 
Statistical Analysis Center (SAC) members and the independent Data Monitoring Board 
(DMB) will have access to unblinded data, as necessary (see Section 8.2.11 for details 
about the interim analysis). 

5.7.  Concomitant Therapy 
Patients are allowed to receive full supportive-care therapies during the study, including 
hormone-replacement therapy.  No other anticancer therapy, immunotherapy (for 
example, trastuzumab), hormonal cancer therapy, or experimental medications will be 
permitted while the patients are participating in this study.  However, localized 
radiotherapy is permitted for palliation of painful lesions at the investigator’s discretion, 
provided the lesions do not represent PD.  Any PD requiring other forms of specific 
antitumor therapy will be cause for discontinuation of study therapy.  Section 5.7.1 
through Section 5.7.6 provide a discussion of the concomitant therapies that warrant 
special attention. 

5.7.1.  Colony Stimulating Factors 
Routine use of colony stimulating factor (CSF) is not permitted during this study.  The 
American Society of Clinical Oncology (ASCO) guidelines for use of CSF should be 
followed (Ozer et al. 2000).  Granulocyte colony-stimulating factor (G-CSF) may be used 
for patients who have ANC <0.5 × 109/L, neutropenic fever, or documented infections 
while neutropenic.  Duration of uncomplicated neutropenia before initiation of G-CSF 
treatment is left to the investigator’s discretion.  G-CSF must be discontinued at least 24 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 38 

hours prior to the start of the next cycle of chemotherapy.  Use of erythropoietin is 
allowed. 

5.7.2.  Nonsteroidal Anti-Inflammatory Drugs 
Patients should not take NSAIDs 2 days before, the day of, and 2 days after pemetrexed 
(or placebo) administration.  If a patient is taking an NSAID with a long half-life (for 
example, naproxen, piroxicam, diflunisal, or nabumetone), it should not be taken 5 days 
before, the day of, or 2 days after receiving pemetrexed (or placebo). 

Concurrent use of aspirin is allowed, up to a maximum dose of 1.3 grams per day. 

5.7.3.  Leucovorin 
Because folic acid and vitamin B12 supplementation has reduced the number of episodes 
of CTCAE Grade 3 and Grade 4 adverse events associated with pemetrexed therapy, the 
sponsor does not anticipate the need for leucovorin as a rescue agent.  However, this 
section provides information on leucovorin rescue if clinically needed.  The protocol 
allows leucovorin rescue in any of the following circumstances: 
•  CTCAE Grade 4 leukopenia lasting longer than 3 days 
•  CTCAE Grade 4 neutropenia lasting longer than 3 days 
• 
• 

immediately for CTCAE Grade 4 thrombocytopenia 

immediately for bleeding associated with CTCAE Grade 3 
thrombocytopenia 

• 

immediately for CTCAE Grade 3 or CTCAE Grade 4 mucositis. 

The following doses and schedules are recommended for intravenous (iv) use: 

• 
• 

leucovorin, 100 mg/m2 iv once; followed by 

leucovorin, 50 mg/m2 iv every 6 hours for 8 days. 

The investigator also may use appropriate doses of the oral formulation at his or her 
discretion. 

5.7.4.  Therapy for Diarrhea 
In the event of diarrhea, the following supportive measures are allowed:  hydration, 
octreotide, and antidiarrheals. 

If diarrhea is severe (requiring intravenous rehydration) and/or associated with fever or 
severe (Grade 3 or 4) neutropenia, broad-spectrum antibiotics must be prescribed.  
Patients with severe diarrhea or any diarrhea associated with severe nausea or vomiting 
must be hospitalized for intravenous hydration and correction of electrolyte imbalances.  

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 39 

5.7.5.  Therapy for Febrile Neutropenia 
Patients experiencing febrile neutropenia, especially with diarrhea or dyspnea, should be 
managed in a hospital setting according to standard procedures, with the urgent initiation 
of intravenous antibiotic therapy. 

5.7.6.  Clinically Significant Effusions 
If a patient develops clinically significant pleural or peritoneal effusions (on the basis of 
symptoms or clinical examination) prior to the first dose of study drug or during therapy, 
draining the effusion prior to dosing is required.  However, if the investigator determines 
that the effusion represents disease progression, the patient should be discontinued from 
study treatment. 

5.8.  Treatment Compliance 
Both pemetrexed and cisplatin will be intravenously administered only at the 
investigational sites by authorized study personnel.  Vitamin B12 supplementation will 
also be administered as an intramuscular injection at the investigational sites.  As a result, 
patient compliance is ensured.  In the period before the first dose of study therapy and 
during therapy, compliance with folic acid supplementation is required and should be 
documented by the investigative sites.  Section 5.5.2.5 provides definitions of sufficient 
folic acid and vitamin B12 therapy. 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 40 

6.  Efficacy, Health Outcome/Quality of Life Measures, 

and Safety Evaluations 

Study procedures and their timing (including tolerance limits for timing) are summarized 
in the Study Schedule, Protocol Attachment JMHR.1.  Sites will assess tumor response in 
patients by using Response Evaluation Criteria In Solid Tumors (RECIST) (Protocol 
Attachment JMHR.5; Therasse et al. 2000). 

6.1.  Efficacy Measures 

6.1.1.  Timing of Measurements 

6.1.1.1.  Baseline and Study Treatment Periods 
Within 4 weeks before first dose of study treatment, baseline tumor measurement(s) will 
be performed on each patient.  Computed tomography (CT) scans (including spiral CT 
scans) and magnetic resonance imaging (MRI) are the preferred methods of 
measurement, but chest x-ray is acceptable if the lesion(s) is/are clearly defined and 
surrounded by aerated lung.  Ultrasound and PET scans will not be permitted as a method 
of lesion measurements.  Within 2 weeks prior to the first dose of study treatment, 
physical examination will be performed for baseline measurement of palpable tumor 
lesions. 

The same method used at baseline must be used consistently for all tumor assessments 
and will be repeated every 6 weeks (± 2 weeks) except in the event of a response.  
Confirmation of response must occur at least 28 days from the first evidence of 
response.  Thereafter, a responding patient will be followed every other cycle per the 
Study Schedule (Protocol Attachment JMHR.1).  The sponsor will collect and store all 
tumor measurement images on all patients throughout the study. 

6.1.1.2.  Postdiscontinuation Period 
Patients in both treatment arms will continue treatment until they require discontinuation 
for one of the reasons cited in Section 4.3 of this document.  Each enrolled patient will 
have a follow-up period when the treatment period is completed. 

Patients who discontinue study treatment for reasons other than objective disease 
progression will be followed at regular intervals for tumor measurement, by the same 
method used at baseline and during the study treatment period, every 6 weeks (±2 weeks) 
until objective disease progression.  For patients who are considered unconfirmed tumor 
responders and discontinue study treatment for reasons other than disease progression, a 
confirmation of tumor response must be documented according to the RECIST guidelines 
(Protocol Attachment JMHR.5; Therasse et al. 2000).  Once the patient has disease 
progression, the patient will be followed every 90 days (±14 days). 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 41 

The date of first documented disease progression must be recorded on the case report 
form (CRF) even if it occurs after the patient has started a new therapy.  
Postdiscontinuation data to be collected will include:  the date of disease progression; 
documentation of any anticancer treatment patient has received including the dates of any 
postdiscontinuation systemic therapy, radiotherapy, or surgical intervention; and the date 
of death.  Patients will be followed until death or study closure (Section 8.2.12). 

6.1.2.  Efficacy Criteria for Tumor Response 
If this Phase 3 study is selected to support a new drug application, or if Lilly requires an 
independent review for any other reason, the response status of all patients may be 
reviewed by an independent panel of clinicians and may be reviewed by Lilly.  In case of 
a discrepancy between the assessment of the independent panel and that of the 
investigator, the independent panel’s assessment will take precedence.  Tumor responses 
will be measured and recorded by using the RECIST guidelines (Protocol Attachment 
JMHR.5; Therasse et al. 2000). 

6.1.2.1.  Best Response 
Best response is determined from the sequence of responses assessed.  For complete 
response (CR) or partial response (PR), best response must be confirmed: a second 
assessment must be performed at least 28 days (and recommended within 42 days) after 
the first documentation of response.  Two objective status determinations of CR before 
progression are required for a best response of CR.  Two determinations of PR or better 
before progression, but not qualifying for a CR, are required for a best response of PR.  
Best response of stable disease (SD) is defined as disease that does not meet the criteria 
for CR, PR or PD and has been evaluated at least once and at least 6 weeks after baseline 
assessment. 

6.1.3.  Definition of Efficacy Measures 
Regarding the time-to-event measures defined below, study enrollment refers to the date 
of randomization. 

The following definitions for efficacy measures will apply: 

•  Overall survival (OS) duration is defined as the time from the date of 

randomization to the date of death from any cause.  For each patient who 
is not known to have died as of the data-inclusion cut-off date, OS 
duration will be censored at the date of the patient’s last contact prior to 
that cut-off date. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 42 

•  Objective progression-free survival (PFS) is defined as the time from 

the date of randomization to the date of objectively determined PD or 
death from any cause, whichever comes first.  For patients who are not 
known to have died as of the data-inclusion cut-off date, and who do not 
have PD, PFS will be censored at the date of the last objective 
progression-free disease assessment prior to the date of any subsequent 
systemic anticancer therapy.  

•  Overall response rate (ORR) is defined as the proportion of patients 

whose best study response is CR or PR.  The response rate is calculated as 
the number of responders (best study response recorded as CR or PR) 
divided by the number of randomized patients. 

•  Duration of response (DoR) is defined as the time from the first 

observation of CR or PR to the first observation of PD or death from any 
cause.  A response is defined as an objective status of CR or PR.  A 
responder is defined as any patient who exhibits a CR or PR.  For patients 
who are not known to have died as of the data-inclusion cut-off date and 
who do not have PD, DoR will be censored at the date of the last objective 
progression-free disease assessment prior to the date of any subsequent 
systemic anticancer therapy. 

6.2.  Health Outcome/Quality-of-Life Measures 
The multiple burdens of cancer and the effects of anticancer treatment can have a 
profound impact on patients’ health-related quality of life (HRQoL).  The Functional 
Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) will be used in 
this study to assess and compare changes in HRQoL between the 2 treatment arms. 

The FACT H&N Version 4 is a reliable and valid instrument to assess HRQoL in patients 
with HNC (List et al. 1996; see Protocol Attachment JMHR.6).  The instrument consists 
of 39 items with 5-point rating scales where 0 equals “not at all” and 4 equals “very 
much.”  It is organized into 5 sections where physical, social/family, and functional 
subscales include 7 items, emotional subscale includes 6 items, and H&N subscale 
includes 12 items. 

The FACT-H&N scores will be calculated based on scoring criteria proposed by the 
developer (Cella 2004).  Results of the FACT-H&N can be reported as the scores for 5 
individual subscales, a FACT-General total score (sum of physical, social/family, 
emotional, and functional well-being subscales), a Trial Outcome Index (TOI) (sum of 
physical well-being, functional well-being, and FACT H&N subscales), and a Total 
FACT-H&N score (sum of FACT-General total score and FACT H&N score).  For all 
reports, a higher score represents a better quality of life. 

Both time to worsening (TTW) and changes from baseline in dimensions of HRQoL 
using FACT-H&N will be compared between treatment arms.  Minimally important 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 43 

difference (MID) for change in scores will be used to determine meaningful differences 
in patients’ FACT-H&N scores (Yost and Eton 2005). 

Trial Outcome Index (TOI) is considered to be a valuable summary measure of physical 
well-being, functional well-being, and disease-specific symptoms (Yost and Eton 2005).  
In patients with recurrent or metastatic HNC, the patients’ well-being (including 
functional/physical abilities and disease-specific symptoms) will generally continue to 
worsen as disease progresses.  Time to worsening (TTW) in TOI is defined as a decrease 
in the TOI score that is considered at least a MID, as compared to the patient’s baseline 
score.  The upper range of MID points (based on the article by Yost and Eton) will be 
used as a guide to determine the meaningful decrease for individual patient’s score.  Time 
to worsening is measured from the date of randomization to the first date of a worsening 
in the TOI (as defined by a decrease from baseline in TOI that is at least the MID) or of 
death from any cause.  For patients who receive any subsequent systemic anticancer 
therapy prior to an observation of worsening, TTW will be censored at the date of the last 
worsening-free assessment prior to the subsequent systemic anticancer therapy.  For 
patients not known to have died or have an observation of worsening as of the data cut-
off date, TTW will be censored at the date of the last worsening-free assessment.  Time to 
worsening in other dimensions of FACT-H&N will be measured in a similar fashion. 

The lower range of MID (based on the article by Yost and Eton 2005) will be used for 
interpreting the group mean change and the upper limit will be used for interpreting the 
change in an individual patient’s score. 

Patients will complete the FACT-H&N prior to randomization, prior to infusion at every 
cycle of therapy (except Cycle 1), a  study-treatment discontinuation, and at 30-day 
postdiscontinuation follow up   Additionally, patients will complete the FACT-H&N 
every 6 weeks after the 30 day postdiscontinuation period until disease progression (refer 
to the Study Schedule in Protocol Attachment JMHR.1 for timing of assessments). 

During the treatment phase of the study, these assessments should be completed at the 
beginning of office visits, before any extensive contact and consultation with the 
clinician/study investigator.  Consultation with the clinician may bias perceptions about 
HRQoL and symptoms and thus affect assessments.  During the treatment period, patients 
will complete questionnaires prior to administration of subsequent cycles of study drug.  
If study drug administration is delayed, it is not necessary to repeat assessments. 

The FACT H&N will be completed by the patient.  Only patients with adequate literacy 
and for whom there is a validated translation in the language in which the patient is fluent 
will be asked to complete any self-administered questionnaires. 

Medical resource utilization data will be collected at each cycle and is largely derived 
from clinical data routinely collected through the CRFs.  These data include length of 
hospitalization, concomitant medications, and transfusions.  Medical resource utilization 
data will be analyzed for exploratory purposes. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 44 

6.3.  Safety Evaluations 
Investigators are responsible for monitoring the safety of patients entered in this study 
and for alerting Lilly or its designee to any event that seems unusual, even if the event 
may be considered an unanticipated benefit to the patient. 

The investigator is responsible for appropriate medical care of patients during the study. 

The investigator remains responsible for following, through an appropriate healthcare 
option, adverse events that are serious or that caused the patient to discontinue before 
completing the study.  The patient should be followed until the event is resolved or 
explained.  Frequency of follow-up evaluation is left to the discretion of the investigator. 

6.3.1.  Adverse Events 

6.3.1.1.  Clinical Adverse Events 
Lilly has standards for reporting adverse events that are to be followed regardless of 
applicable regulatory requirements that may be less stringent   For purposes of collecting 
and evaluating all information about Lilly drugs or drug delivery systems used in clinical 
trials, a clinical trial adverse event is any untoward medical occurrence in a patient 
administered a pharmaceutical product, without regard to the possibility of a causal 
relationship. 

Lack of drug effect is not an adverse event in clinical trials because the purpose of the 
clinical trial is to establish drug effect  

Cases of pregnancy that occur during maternal or paternal exposures to study drug or 
drug delivery system should be reported for tracking purposes.  Data on fetal outcome 
and breast-feeding are collected for regulatory reporting and drug safety evaluation. 

Study site personnel will record the occurrence and nature of each patient’s preexisting 
conditions. 

During the study, site personnel will record any change in the condition(s) and the 
occurrence and nature of any adverse events. 

If a patient never receives study drug, but experiences an adverse event after the 
informed consent document (ICD) is signed, ONLY events the investigator believes may 
have been caused by a protocol procedure will be reported to Lilly or its designee via the 
CRF. 

All adverse events occurring after enrollment must be reported to Lilly or its designee by 
CRF. 

Investigators will be instructed to report to Lilly or its designee their assessment of the 
potential relatedness of each adverse event to protocol procedure, studied disease state, 
study drug and/or drug delivery system via CRF. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 45 

In addition, study site personnel must report to Lilly or its designee immediately any 
SAEs or any instance where the investigator unblinds a patient's treatment group 
assignment for any other reason.  Remember that all adverse events must be reported by 
CRF, even if a telephone report has been made. 

If a patient's dosage is reduced or treatment is discontinued as a result of an adverse 
event, study site personnel must clearly report to Lilly or its designee via CRF the 
circumstances and data leading to any dosage reduction or discontinuation of treatment. 

Events leading to the clinical outcome of death from PD will be included as part of the 
safety and efficacy analyses for this study and will not be recorded as adverse events 
unless the investigator believes that the events may have been caused by the study drug. 

In cases where the investigator notices an unanticipated benefit to the patient, study site 
personnel should report “unexpected benefit” with the actual event term to Lilly or its 
designee via CRF (for example, the complete actual term would be “unexpected 
benefit—sleeping longer”). 

Thirty-day postdiscontinuation follow-up:  Each patient will have a 30-day 
postdiscontinuation follow-up evaluation.  This follow-up period is defined as a period of 
approximately 30 days commencing with the patient discontinuation from the treatment 
portion of the study, rather than with patient’s last dose of the study drug.  The start date 
of the first postdiscontinuation follow-up period should equal the date of patient 
discontinuation.  During this period, all ongoing or new adverse events, regardless of 
relatedness to study treatment or protocol procedure, must be evaluated and recorded on 
the CRF.  Any event deemed serious within the 30-day follow-up period, regardless of 
relatedness to study treatment or protocol procedure, must be reported immediately to 
Lilly or its designee and recorded on the CRF (refer to Section 6.3.1.3). 

Long-term follow-up:  After the 30-day postdiscontinuation follow-up, only adverse 
events thought to be related to study treatment or protocol procedures and deemed serious 
should be documented on the CRF.  Ongoing adverse events related to study treatment or 
protocol procedures will be followed until their remission or stabilization.  Serious 
adverse events determined to be related to study therapy also should be reported 
immediately to Lilly or its designee via the designated transmission method (refer to 
Section 6.3.1.3). 

6.3.1.2.  Serious Adverse Events 
Study site personnel must notify Lilly or its designee immediately, by the designated 
transmission method, any adverse event from the study that results in one of the 
following outcomes, or is significant for any other reason: 

•  death (excluding death due to progression of study disease) 
• 
•  a life-threatening experience (that is, immediate risk of dying) 

initial or prolonged inpatient hospitalization 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 46 

•  persistent or significant disability/incapacity 
•  congenital anomaly/birth defect. 

Any SAEs occurring prior to enrollment that the investigator believes may have been 
caused by a protocol procedure must be reported immediately to Lilly or its designee and 
recorded on the case report form. 

Study-specific clinical outcomes of death from PD should be reported as an SAE only if 
the investigator deems them related to use of the study drug. 

6.3.1.3.  Postdiscontinuation Safety Follow-Up  
For all patients, a follow-up visit will occur approximately 30 days after discontinuation 
from study treatment.  Evaluation at the 30-day postdiscontinuation visit will include: 

•  chemistry and hematology assessments 
•  CTCAE ratings (if delayed adverse events related to study drugs are 

observed, the patient must be assessed approximately every 30 days until 
adverse events resolve or stabilize) 

• 

report of postdiscontinuation adverse events, including the following: 

○  any adverse events, regardless of relatedness to study therapy, that 

occurred after discontinuation of study treatment 

○  outcome of any residual adverse events at the time of 

discontinuation of treatment 

○  documentation of date of death, if death has occurred 

○  key concomitant medications 

○  hospitalizations 

○ 

transfusions. 

After the 30-day postdiscontinuation follow up, only SAEs thought to be related to study 
treatment or protocol procedures should be reported immediately to Lilly or its designee 
via the designated transmission method and recorded on the CRF.  For these events, the 
patient must be followed every 30 days (until the event has resolved, stabilized, or until 
the initiation of a new systemic anticancer therapy). 

6.3.2.  Laboratory Tests  
Please refer to Protocol Attachment JMHR.2 for the listing of laboratory tests to be 
performed for this study.  Refer to the Study Schedule (Protocol Attachment JMHR.1) for 
the timing of laboratory tests and clinical procedures.  Laboratory analysis results that 
would unblind the study will not be reported to investigational sites or other blinded 
personnel until the study has been unblinded. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 47 

6.3.2.1.  Limited Use Samples for Standard Laboratory Testing  
Blood samples will be collected at the times specified in the Study Schedule (Protocol 
Attachment JMHR.1).  Standard laboratory tests including chemistry and hematology 
panels will be performed.  A serum or urine pregnancy test (if applicable) will be 
performed at the investigative site or at a local laboratory.  Other clinical laboratory tests 
may be analyzed by a central laboratory.  Protocol Attachment JMHR.2 lists the specific 
tests that will be performed for the study. 

Samples collected for specified laboratory tests will be destroyed within 60 days of 
receipt of confirmed test results.  Certain samples may be retained for a longer period of 
time, if necessary, to comply with applicable laws, regulations, or international laboratory 
certification standards. 

6.3.2.2.  Samples for Translational Research 
As part of Lilly’s ongoing efforts to understand the relationship between cancer, genetics, 
and response to therapy, this study will analyze biomarkers relevant to pemetrexed and 
cisplatin and to the disease state.  The study will also analyze the correlation between 
biomarkers and clinical outcome.  All sites are required to participate in this translational 
research, with the exception of sites where local regulations prohibit or limit this activity.  
Patient participation in this portion of the study is optional. 

Formalin-fixed, paraffin-embedded (FFPE) tissue will be collected from the tumor 
sample taken to make the initial histologic diagnosis of cancer or from the biopsy for 
recurrent disease based on availability.  The tissue will be used for research aimed at 
identifying markers for predicting clinical outcome to treatment with pemetrexed and 
cisplatin. 

Patients will not receive the translational research results at end of study.  Tissue samples 
may be collected for gene expression using microarrays and/or immunohistochemical 
(IHC) analyses, such as: 

• 

• 

• 

thymidylate synthase (TS):  TS is a direct enzyme target of pemetrexed 
and plays an essential role in DNA synthesis.  Evidence suggests that high 
levels of TS may represent a resistance state to anti-folates 

folate receptor-alpha (FR-α):  FR-α is a membrane transporter of folates 
and may contribute to concentration of pemetrexed into the tumor cell 

folylpolyglutamyl synthetase (FPGS):  FPGS is an enzyme responsible for 
polyglutamation of pemetrexed.  This results in higher affinity binding of 
pemetrexed to both the folate-dependent enzymes TS and glycinamide 
ribonucleotide formyltransferase (GARFT) 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 48 

•  excision-repair cross-complementing rodent repair deficiency 1 (ERCC1):  

ERCC1 is a DNA repair enzyme thought to play a role in sensitivity to 
platinum agents.  High ERCC1 levels may represent an ability for the 
tumor to repair cleavage induced by platinum agents and thus, a marker of 
resistance. 

The information from the expression profiles generated on a candidate gene level or by 
Affymetrix gene chips or equivalent, for example, may be used to correlate clinical 
outcome with potential changes in RNA/DNA levels.  Other markers of interest may be 
examined, based on evolving information at the time the laboratory assessments are done, 
given adequate material.  Taken collectively, these evaluations may assist in 
understanding the biology of head and neck cancer in this group of patients and their 
response to therapy. 

6.3.2.2.1.  Stored Samples 
Patients will have the option to participate in a portion of this study that involves storage 
of identifiable tissue samples (for example, trial patient numbers) for possible future 
research. 

Stored samples will retain the patient identifier and therefore will not be stored 
indefinitely.  Samples will be stored in the US for a maximum of 5 years after the last 
patient visit for the study; any sample remaining at that time will be destroyed. 

6.3.2.2.2.  Collection Procedures 
Samples will be shipped by the central laboratory to the designated research laboratories 
that are associated with Lilly and are located in the US. 

Tumor tissue samples should be prepared and shipped for analysis within 4 weeks of 
randomization. 

All samples will be labeled with the same identification code assigned to each patient in 
the clinical study.  This code will be used in lieu of the patient’s name to protect the 
patient’s identity. 

Samples must be prepared in accordance with the instructions on the lab requisition.  At 
baseline visit, before the patient receives study treatment, the following samples will be 
collected: 

•  pretreatment FFPE tumor tissue sample taken from the original diagnostic 

tumor specimen or from the biopsy at recurrent disease. 

6.3.3.  Other Safety Measures 
Other safety measures include physical examinations and adverse event ratings.  Patients 
will be rated for adverse events before each cycle using the CTCAE grade (Version 3.0, 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 49 

NCI 2003).  See the Cancer Therapy Evaluation Program Common Terminology Criteria 
(Version 3.0; NCI 2003), supplied with the CRFs. 

6.3.4.  Safety Monitoring 
The Lilly CRP will monitor safety data throughout the course of the study.  The Lilly 
CRP will review SAEs within time frames mandated by company procedures and will 
review trends, laboratory analyses, and adverse events at periodic intervals. 

For the purpose of the study, all deaths and SAE reports will be reviewed in a blinded 
fashion by Lilly during the clinical trial.  These reports will be reviewed to ensure 
completeness and accuracy but will not be unblinded to Lilly during the clinical trial.  If a 
death or SAEs occurs, only the Lilly Global Product Safety (GPS) associate will be 
nblended for regulatory reporting and safety monitoring purposes.  These measures will 
preserve the integrity of the data collected during the clinical trial and minimize any 
potential for bias while providing for appropriate safety monitoring. 

6.3.5.  Complaint Handling 
Lilly collects complaints on all study drugs and drug delivery systems used in clinical 
trials in order to ensure the safety of study par icipants, monitor quality, and make 
product improvements. 

The investigator or his/her designee is responsible for handling the following aspects of 
the complaint process in accordance with the instructions provided for the study: 

recording a complete description of the product complaint reported 

• 
•  completing a formal complaint report using the study specific complaint 

forms provided for this purpose 

•  determining when a drug/drug delivery system is to be returned. 

6.4.  Appropriateness of Measurements 
All efficacy and safety assessments used in this study are appropriate for a Phase 3 
oncology study. 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 50 

7.  Data Quality Assurance 

To ensure accurate, complete, and reliable data, Lilly or its representatives will do the 
following: 

•  provide instructional material to the study sites, as appropriate 
• 

sponsor a start-up training session to instruct the investigators and study 
coordinators.  This session will give instruction on the protocol, the 
completion of the CRFs, and study procedures 

•  make periodic visits to the study site 
•  be available for consultation and stay in contact with the study site 

personnel by mail, telephone, and/or fax 

• 

review and evaluate CRF data and use standard computer edits to detect 
errors in data collection 

•  verify the quality of the data. 

In addition, Lilly or its representatives may periodically check a sample of the patient 
data recorded against source documents at the study site.  The study may be audited by 
Lilly Medical Quality Assurance (MQA) or its representatives, and/or regulatory 
agencies at any time.  Investigators will be given notice before an audit occurs. 

To ensure the safety of participants in the study and to ensure accurate, complete, and 
reliable data, the investigator will keep records of laboratory tests, clinical notes, and 
patient medical records in the patient files as original source documents for the study.  If 
requested, the investigator will provide the sponsor, applicable regulatory agencies, and 
applicable ethical review boards with direct access to original source documents. 

7.1.  Data Entry and Computerized Systems 
The CRF data will be encoded and stored in a comprehensive computerized clinical 
research system intended for collecting, managing, and reviewing clinical study data. 

Central laboratory data will be stored electronically in the central laboratory’s database 
system.  Data subsequently will be transferred from the contract laboratory to the Lilly 
generic laboratories system. 

Any data for which the CRF will serve as the source document will be identified and 
documented by each site in that site’s study file. 

Data from complaint forms submitted to Lilly will be encoded and stored in the global 
complaint management system. 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 51 

8.  Sample Size and Statistical Methods 

8.1.  Determination of Sample Size 
The study will enroll approximately 790 patients in 1:1 randomization (395 patients in 
Treatment Arm A and 395 patients in Treatment Arm B), and the sponsor will perform 
the final analysis after 632 deaths have occurred (that is, 20% censoring rate) to compare 
OS in patients treated with pemetrexed plus cisplatin versus patients treated with cisplatin 
alone.  Based on results from the Burtness trial (refer to Table JMHR.1), the median OS 
with single-agent cisplatin was estimated to be 8 months (Burtness et al. 2005).  This 
study is powered to detect a 25% improvement in OS when pemetrexed is combined with 
cisplatin by showing a median OS of 10 months with pemetrexed plus cisplatin.  
Assuming that the true survival hazard ratio (HR) of pemetrexed plus cisplatin to 
cisplatin alone is 0.80, the study has 80% power to achieve statistical significance at a 
two-sided level of 0.05. 
 
An interim analysis for futility is planned for this study.  The interim analysis will be 
performed to assess safety and efficacy in order to determine whether it is scientifically 
and ethically appropriate to continue enrollment   The futility analysis will be based on 
PFS as the OS data is not anticipated to mature at the time of interim analysis.  The 
interim analysis will be conducted when approximately 300 patients have experienced 
disease progression or have died.  All available data (from the randomized patients) prior 
to this cut-off date will be included in the interim analysis.  Patient enrollment will 
continue during the interim analysis (See Section 8.2.11 regarding details about the 
interim analysis).  Because the interim analysis is strictly for futility, the test for positive 
efficacy should not and will not be performed, and the trial can only be stopped due to 
lack of efficacy.  Thus, the type-I error for the final analysis of PFS will not be adjusted. 

8.2.  Statistical and Analytical Plans 

8.2.1.  General Considerations 
Statistical analysis of this study will be the responsibility of the Eli Lilly and Company.  
The interpretation of study results will be the responsibility of the Lilly CRP and the 
statistician. The Lilly CRP and the statistician will also be responsible for the appropriate 
conduct of an internal review process for both the final study report and any study-related 
material to be authorized for publication. 

Any change to the data analysis methods described in the protocol will require an 
amendment ONLY if it changes a principal feature of the protocol.  Before any 
unblinding of the aggregate database, minor modifications or clarifications to the data 
analysis methods will be described and justified in the statistical analysis plan. Any 
retrospective or exploratory analyses not defined by the protocol or the statistical analysis 
plan will be explained in the clinical study report. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version All tests of treatment effects will be conducted at a two-sided alpha level of 0.05, all tests 
of interactions will be conducted at a two-sided level of 0.10, and all confidence intervals 
will be given at a two-sided 95% level, unless otherwise stated. 

Page 52 

8.2.1.1.  Qualifications for Efficacy Analysis 
The following are the qualifications for the analyses of efficacy parameters: 

•  OS, PFS, and ORR:  All randomized patients (intention-to-treat [ITT] 

population). 

•  DoR:  All randomized patients with a confirmed best response of CR or 

PR. 

8.2.1.2.  Qualifications for Health Outcome/Quality-of-Life Analysis 
The following are qualifications for the analyses of health outcome analyses: 

•  All randomized patients with a baseline FACT-H&N assessment will be 

included in the analysis of TTW. 

•  All randomized patients with a baseline FACT-H&N assessment and at 
least 1 post-randomization assessment will be included in the analysis of 
change from baseline. 

8.2.1.3.  Qualifications for Safety Analysis 
All randomized patients who receive at least 1 dose of study drug (pemetrexed, cisplatin, 
or placebo) will be evaluated for safety. 

8.2.2.  Patient Disposition 
A detailed description of patient disposition will be provided.  It will include: 

•  A definition of patient qualification 
•  A summary of data on patient discontinuation 
•  A summary of data on overall qualification status of all patients 
•  An account of all identified protocol violations. 

All patients entered in the study will be accounted for in the summation.  The number of 
patients who do not qualify for analysis, who die, or who discontinue before treatment 
begins will be specified.  

8.2.3.  Patient Characteristics 
Patient characteristics will include a summary of the following: 

•  patient demographics 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 53 

•  baseline disease characteristics 
•  pre-existing conditions 
•  prior therapies 
•  concomitant drugs. 

Other patient characteristics will be summarized as deemed appropriate. 

8.2.4.  Concomitant Therapy 
Concomitant medications will be summarized for all randomized patients per treatment 
arm. 

8.2.5.  Treatment Compliance 
Only authorized study personnel at the investigative sites will administer pemetrexed and 
cisplatin.  Study personnel also will administer vitamin B12 as an intramuscular injection 
at the investigative sites.  As a result, the sites ensure patient compliance. 

Dose omissions, reductions, and delays will be summarized for all randomized patients 
per treatment arm. 

8.2.6.  Efficacy Analyses 

8.2.6.1.  Primary Outcome and Methodology 
The primary outcome measure for this trial is OS.  All randomized patients will be 
included in the analysis of OS.  The primary analysis will be the comparison of OS 
between the 2 study treatments using a stratified log-rank test at two-sided α=0.05 with 
the following prognostic variables as stratification factors:  performance status (0 or 1 
versus 2), previously treated for HNC (no versus yes), distant metastasis (no versus yes), 
and prior platinum-based therapy (no versus yes).  Kaplan-Meier (K-M) estimation 
(Kaplan and Meier 1958) including generating K-M curve, quartiles, and interval 
estimation using 95% confidence intervals will also be done.  The supportive analysis of 
the primary outcome will be performed to obtain treatment effect after adjusting for the 
prognostic variables using Cox regression model (Cox 1972). 

8.2.6.2.  Secondary Endpoints 
The secondary efficacy endpoints are objective PFS, ORR, and DoR. 

•  For each of the time-to-event endpoints (PFS and DoR), the following 

analyses will be performed:   

○  Kaplan-Meier estimation including generating K-M curve, 

quartiles, and interval estimation using 95% confidence intervals. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 54 

○  Stratified log-rank test stratified by the following prognostic 

variables: performance status (0 or 1 versus 2), previously treated 
for HNC (no versus yes), distant metastasis (no versus yes), and 
prior platinum-based therapy (no versus yes). 

○  Cox regression model to obtain treatment effect after adjusting for 

the prognostic variables. 

•  ORR will be compared between treatment arms based on an unadjusted, 

normal distribution approximation for the difference in rates.  A 95% 
confidence interval for the response rate of each arm will be calculated 
using an exact method. 

All randomized patients who were assigned to treatment will be included in the analysis 
of PFS and ORR.  The patient population for DoR is all randomized patients with a 
confirmed response. 

Overall response rate will be estimated by dividing the total number of confirmed CR or 
PR by the total number of patients randomized. 

Patients who discontinue before the study endpoint is reached without disease 
progression or death due to any cause will have their overall tumor response assessed per 
protocol and will be included in the analysis. 

8.2.7.  Quality-of-Life Analysis 
The HRQoL data, as measured by the FACT-H&N, will be collected.  There are 5 
subscale scores (physical well-being, social/family well-being, emotional well-being, 
functional well-being, and H&N tumor subscales), a TOI score, a FACT-General total 
score, and a total FACT-H&N score. 

The time-to-worsening variables, including TTW in TOI, will be analyzed using the same 
methods mentioned for other time-to-event variables (see Section 8.2.6.2).  All 
randomized patients with a baseline assessment will be included in the TTW analyses. 

The change from baseline in subscale scores, TOI score, FACT-General total score, and 
Total FACT-H&N score will be analyzed using Mixed Model Repeated Measure analysis 
with treatment, baseline score, visit, treatment-by-visit interaction as fixed effects, and 
with patient nested in treatment as random effect in the model.  Within-subject 
correlation over time will be accounted for through compound symmetric covariance 
matrix.  The model will be fit using the restricted maximum likelihood method (REML).  
The significance of comparison between treatments for each visit will be based on the 
contrast of least square means (LSMeans).  The average of the LSMeans (over the 
number of visits) for each treatment group will also be compared and tested.  
Satterthwaite’s approximation will be used to estimate degrees of freedom.  All 
randomized patients with baseline and at least 1 post-baseline measure will be included in 
the change from baseline analysis. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 55 

Internal consistency of baseline data for FACT-H&N subscales will be tested using 
Cronbach’s alpha method.  Medical resource utilization data will be summarized by each 
treatment arm for all randomized patients who received at least 1 dose of study drug. 

8.2.8.  Statistical Strategy for Analyzing Selected Efficacy 

Endpoints 

To establish PFS, ORR, and FACT-H&N functional efficacy in the study while 
controlling for type I error, a gatekeeping strategy will be applied in analyzing these 
endpoints.  The endpoints will be analyzed with a two-sided 0.05 level of significance 
with the following chronological order: 

1.  PFS 

2.  ORR 

3.  TTW in TOI from FACT-H&N instrument 

8.2.9.  Safety Analyses 
The safety evaluation will include all patients who receive at least 1 dose of study 
therapy, including saline placebo.  Safety analyses will include summaries of the 
following: 

•  maximum CTCAE grades for laboratory and nonlaboratory adverse 

events. 

treatment-emergent adverse events (TEAEs) 

• 
•  adverse events causing discontinuation from the study 
•  SAEs causing discontinuation from the study 
•  hospitalizations 
•  blood transfusions. 

The incidences of selected adverse events from the two treatment arms will be compared 
using Fisher’s Exact test. 

8.2.10. Subgroup Analyses  
Subgroup analyses on OS and objective PFS will be conducted on important subgroups 
of patients.  These subgroups are ECOG performance status (0 or 1 versus 2), previously 
treated for HNC (no versus yes), distant metastasis (no versus yes), prior platinum-based 
therapy (no versus yes), age (<50 versus ≥50), sex (male versus female), race (Caucasian 
versus Non-Caucasian), and prior surgery or radiotherapy within 6 months of 
randomization (no versus yes). 

Additional subgroup analyses will be performed as deemed appropriate. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 56 

8.2.11. Interim Analyses 
There is one interim analysis planned for this study.  The interim analysis will be 
performed to assess safety and efficacy in order to determine whether it is scientifically 
and ethically appropriate to continue enrollment. The OS data is anticipated to be 
preliminary (with high censoring) at the time of interim analysis, and it is assumed that 
PFS is a reasonable surrogate for OS.  Therefore, the question of whether there is 
evidence of a lack of efficacy for pemetrexed plus cisplatin (relative to placebo plus 
cisplatin) will be evaluated based on an interim analysis of PFS (one of the secondary 
endpoints of the study).  The interim analysis will calculate conditional power after 
approximately 300 patients have had disease progression or have died.  It is anticipated 
that the interim analysis will be conducted after approximately 400 patients have been 
enrolled into the trial.  The data inclusion cut-off date for this analysis will be fixed when 
approximately 300 PFS events have been observed.  All available data (from randomized 
patients) prior to this cut-off date will be included in the interim analysis. 

The trial enrollment may be stopped following this interim analysis, but only if the 
experimental arm shows evidence of unacceptable toxicity or a lack of efficacy for 
pemetrexed plus cisplatin over placebo plus cisplatin. 

 
This futility analysis based on PFS can be described as follows: 

The natural logarithm of the PFS hazard ratio (for pemetrexed plus cisplatin over placebo 
plus cisplatin) will be estimated using the Cox model with 5 covariates (assigned 
treatment arm, ECOG performance status, previously treated for HNC, distant metastasis, 
and prior platinum based therapy)  

Conditional on this interim estimate for the PFS HR, assuming the true PFS HR is 0.78, 
and assuming the number of PFS events at the final analysis will be 700 (88.6% of 790), 
the conditional statistical power of the final analysis of PFS will be calculated (Crowley 
and Ankert 2006).  If this conditional power is strictly less than 0.741, then the DMB 
should recommend that study enrollment be stopped.  Attachment JMHR.7 provides the 
formula used to calculate conditional statistical power. 

Assuming exactly 300 PFS events are included in this interim analysis, the operating 
characteristics for this futility test are shown in Table JMHR.7. 

Table JMHR.7. 

Operating Characteristics for the Futility Test 

Probability of not 
stopping 
(HR = 1.00) 
19.3% 
 

Probability of 

stopping 

(HR = 0.78) 

9.9% 

Stopping rule 

based on 

conditional power 

< 74.1% 

Stopping rule 

Minimum 

based on interim 

conditional power 

HR estimate 

≥ 0.90 

(HR = 0.78) 

74.1% 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 57 

Since the stopping rules are based on some assumptions, the threshold values (the interim 
HR and the conditional power) should be viewed only as a guidance, not the absolute 
rule, for interim decision making.  Analyses of safety data at interim will be performed as 
described in Section 8.2.9.  At the interim analysis, the DMB may also recommend that 
trial enrollment be stopped if the experimental arm shows evidence of unacceptable 
toxicity. 
 
The overall survival or any other efficacy data will not be analyzed and will not be 
reported at the interim analysis. 
 
During the interim analysis, patient accrual will continue.  A Data Monitoring Board 
(DMB) will be formed in accordance with Lilly policies and procedures and will be 
responsible for evaluating interim results.  Interim analysis will be conducted according 
to the DMB charter.  A number of individuals outside the DMB will form the Statistical 
Analysis Center (SAC), a group that will be responsible for ensuring the accuracy of 
interim data and preparing interim summaries and analyses for the DMB.  The SAC 
members will have access to interim data as needed to validate data and facilitate the 
DMB’s review.  The SAC members will be limited to a minimal number of individuals 
needed for this role.  The DMB and SAC members will be external to Lilly.  The SAC 
members will not be allowed to disseminate any information pertaining to interim data 
other than to members of the SAC or the DMB.  Only the DMB is authorized to review 
completely unblinded interim analyses.  Study sites will receive information about 
interim results ONLY if they need to know for the safety of their patients. 

8.2.12. Criteria for End of Study 
The study will end when data collection is stopped.  The study design is to enroll 790 
patients and perform a final analysis after approximately 632 deaths have been observed, 
at which time database lock will occur.  Lilly has the right to stop collecting data after the 
database has been locked; however, after the final analysis, data may continue to be 
collected on surviving patients.  If further data are collected that are not included as part 
of the final locked database, the postlock data will eventually be combined with the 
locked database and stored in a data library separate from the locked database.  The 
clinical study report will not be revised to reflect these additional data. 

8.2.13. Translational Research Analyses 
The distributions of biomarkers with continuous measures, such as gene or protein 
expression, will be described for total patient population and by treatment arms.  
Summary statistics will include means, medians, corresponding standard errors, quartiles, 
and ranges.  Biomarkers with discrete measures, such as genotype locus or IHC-staining-
assessed protein expression, will be summarized in frequency tables for total population 
and by treatment arm. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 58 

A Cox regression analysis of time-to-event variables such as OS and PFS will be 
performed with each gene measured fit as a single covariate, using the following 
additional baseline covariates:  assigned study treatment arm (pemetrexed plus cisplatin 
versus placebo plus cisplatin), performance status (0 or 1 versus 2), previously treated for 
HNC (no versus yes), distant metastasis (no versus yes), and prior platinum-based 
therapy (no versus yes).  The covariates in the model correspond to the study 
randomization factors.  The Cox regression analysis of OS and PFS, will be repeated with 
gene expression level data, along with interaction with treatment in the analytical model.  
In addition, a Cox multiple regression analysis with those genes identified as significant 
will be performed to look for interactions between multiple genes.  Logistic regressions 
of best tumor response on gene expression will be done for each gene, using methods 
analogous to those described above for the Cox regression analyses.  The protein 
expression data will be analyzed in similar manner as gene expression. 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 59 

9. 

Informed Consent, Ethical Review, and Regulatory 

Considerations 

Informed Consent 

9.1. 
The investigator is responsible for ensuring that the patient understands the risks and 
benefits of participating in the study, including answering any questions the patient may 
have throughout the study and sharing any new information that may be relevant to the 
patient's willingness to continue his or her participation in the trial in a timely manner. 

The informed consent document will be used to explain the risks and benefits of study 
participation to the patient in simple terms before the patient is entered into the study, and 
to document that the patient is satisfied with his or her understanding of the risks and 
benefits of participating in the study and desires to participate in the study. 

The investigator is responsible for ensuring that informed consent is given by each 
patient or legal representative.  This includes obtaining the appropriate signatures and 
dates on the informed consent document prior to the performance of any protocol 
procedures and prior to the administration of study drug. 

As used in this protocol, the term "informed consent" includes all consent and assent 
given by patients or their legal representatives. 

9.2.  Ethical Review 
Lilly must agree with all informed consent documents before they are submitted to the 
ethical review board and are used at investigative sites(s).  All informed consent 
documents must be compliant with the International Conference on Harmonisation 
guideline on GCP.  Informed consent obtained under special circumstances may occur 
only if allowed by local laws and regulations, and performed in accordance with a written 
process approved by Lilly. 

Documentation of ethical review board approval of the protocol and the informed consent 
document must be provided to Lilly before the study may begin at the investigative 
site(s).  The ethical review board(s) will review the protocol as required. 

Any member of the ethical review board who is directly affiliated with this study as an 
investigator or as site personnel must abstain from the ethical review board’s vote on the 
approval of the protocol. 

The study site’s ethical review board(s) should be provided with the following: 

• 

• 

the current Clinical Investigator’s Brochure or package labeling and 
updates during the course of the study 

informed consent document 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 60 

• 

relevant curricula vitae. 

9.3.  Regulatory Considerations 
This study will be conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki and that are consistent with good clinical practices 
and the applicable laws and regulations.  The investigator, head of the medical institution, 
or designee will promptly submit the protocol to applicable ethical review board(s). 

An identification code assigned by the investigator to each patient will be used in lieu of 
the patient's name to protect the patient’s identity when reporting adverse events and/or 
other trial-related data. 

9.3.1.  Investigator Information 
Physicians with a specialty in oncology will participate as investigators in this clinical 
trial. 

9.3.2.  Protocol Signatures 
After reading the protocol, each principal investigator will sign the protocol signature 
page and send a copy of the signed page to a Lilly representative. 

9.3.3.  Final Report Signature 
The clinical study report coordinating investigator will sign the final clinical study report 
for this study, indicating agreement that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study. 

The sponsor’s responsible medical officer will sign the final clinical study report for this 
study, confirming that to the best of his or her knowledge, the report accurately describes 
the conduct and results of the study. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 61 

10. References 

Bunn P, Paoletti P, Niyikiza C, Rusthoven J, Nelson K, Hanauske A, Stabler S, Calvert 
AH, Allen R. 2001. Vitamin B12 and folate reduce toxicity of ALIMTA (pemetrexed 
disodium, LY231514, MTA), a novel antifolate/antimetabolite [abstract]. In: Proc Am 
Soc Clin Oncol 37th annual meeting program/proceedings; 2001 May 12-15; San 
Francisco. Alexandra (VA): American Society of Clinical Oncology. 20(1):76a. 
Abstract 300. 

Burtness B, Goldwasser MA, Flood W, Matter B, Forastiere AA. 2005. Phase III 

Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab 
in Metastatic/Recurrent Head and Neck Cancer:  An Eastern Cooperative Oncology 
Group Study. J Clin Oncol 23(34):8646-8654. 

Cella D (ed). 2004. Manual of the Functional Assessment of Chronic Illness Therapy 
(FACIT) measurement system  (Version 4.1). Evanston, IL: Center on Outcomes, 
Research and Education (CORE), Evanston Northwestern Health Care and 
Northwestern University. 

Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, 
Tueni EA, Verweij J, Wildiers J, Clerico M, Dalesio O, Kirkpatrick A, Snow GB. 
1994. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine 
(CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or 
metastatic squamous cell carcinoma of the head and neck: a phase III study of the 
EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5(6):521-526. 

Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum 

creatinine. Nephron 16(1):31-41. 

Cox DR. 1972. Regression models and life tables (with discussion). J Royal Stat Soc B 

74(2):187-220. 

Cristy M, Eckerman KF. 1987. Specific absorbed fractions of energy at various ages from 

internal sources: I. methods. Prepared by the Oak Ridge National Laboratory, Oak 
Ridge, Tenn. 

Crowley J, Ankert DP, editors. 2006. Handbook of Statistics in Clinical Oncology. 2nd 

ed. Boca Raton, FL: CRC Press. p 232-233. 

Forastiere A, Ang K, Brizel D, Brockstein BE, Dunphy F, Eisele DW, Goepfert H, Hicks 
WL Jr, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mittal BB, Pfister DG, Pinto 
HA, Posner MR, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, 
Wheeler RH 3rd, Wolf GT, Worden F, Yueh B; National Comprehensive Cancer 
Network. 2005. Head and Neck Cancers.  J Natl Compr Canc Netw 3(3):316-91. 

Forastiere A, Koch W, Trotti A, Sidransky D. 2001. Head and neck cancer [erratum in: N 

Engl J Med 346(10):788]. N Engl J Med 345(26):1890-1900. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 62 

Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, 

McClure S, VonFeldt E, Williamson SK, Von Hoff DD. 1992. Randomized 
comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus 
methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest 
Oncology Group study. J Clin Oncol 10(8):1245-1251. 

Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. 1985. Comparison of 

methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the 
head and neck region: a Southwest Oncology Group study. Cancer Treat Rep 
69(6):577-581. 

Habeck LL, Mendelsohn LG, Shih C, Taylor EC, Colman PD, Gossett LS, Leitner TA, 

Schultz RM, Andis SL, Moran RG. 1995. Substrate specificity of mammalian 
folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol 
Pharmacol 48(2):326-333. 

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier 

U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, 
Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr  2004. Randomized phase III 
trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer 
previously treated with chemotherapy. J Clin Oncol 22(9):1589-1597. 

Hong WK, Schaefer S, Issell B, Cummings C, Luedke D, Bromer R, Fofonoff S, D'Aoust 

J, Shapshay S, Welch J, Levin E, Vincent M, Vaughan C, Strong S. 1983. A 
prospective randomized trial of methotrexate versus cisplatin in the treatment of 
recurrent squamous cell carcinoma of the head and neck. Cancer 52(2):206-210. 

Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough 

LT, Mortimer JE, Einhorn LH, Schacter L, Cherng N, Dalton T, Burroughs J, 
Rozencweig M. 1992. A phase III randomized study comparing cisplatin and 
fluorouracil as single agents and in combination for advanced squamous cell carcinoma 
of the head and neck. J Clin Oncol 10(2):257-263. 

Kaplan EL, Meier P. 1958. Nonparametric estimation of incomplete observations. J Am 

Stat Assoc 53:457-481. 

List MA, D'Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, Vokes E. 1996. The 

Performance Status Scale for Head and Neck cancer patients and the Functional 
Assessment of Cancer Therapy-Head and Neck (FACT-H&N) scale: A study of utility 
and validity. Cancer  77(11): 2294-2301. 

Liverpool Head and Neck Oncology Group.1990. A phase III randomised trial of 

cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end 
stage squamous carcinoma of the head and neck. Br J Cancer 61(2):311-315. 

Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M, Veevers A, 
Stell PM. 1985. Cisplatinum and bleomycin for advanced or recurrent squamous cell 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 63 

carcinoma of the head and neck: a randomized factorial phase III controlled trial. 
Cancer Chemother Pharmacol 15(3):283-289. 

Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, 
Paoletti P, Calvert AH, Allen RH. 2002. Homocysteine and methylmalonic acid: 
markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 
1(7):545-552. 

[NCI] National Cancer Institute. 1993. Investigational agent adverse drug reaction 

reporting chart. p 153-157. 

[NCI] National Cancer Institute. 1998. Common Toxicity Criteria (CTC). Version 2.0. 
Available at: http://ctep.cancer.gov/reporting/CTC-3.html. Accessed 17 June 2005. 

[NCI] National Cancer Institute. 2003. Cancer therapy evaluation program common 

terminology criteria for adverse events, version 3.0. Available at 
http://ctep.cancer.gov/reporting/ctcnew.html. Accessed 11 May 2006. 

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. 

1982. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J 
Clin Oncol 5:649-655. 

Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, 

Smith TJ, Somlo G, Wade JC, Wade JL 3rd, Winn RJ, Wozniak AJ, Somerfield MR, 
for the American Society of Clinical Oncology. 2000. 2000 update of 
recommendations for the use of hematopoietic colony-stimulating factors: evidence-
based, clinical practice guidelines  J Clin Oncol 18(20):3558-3585. 

Pocock SJ, Simon R. 1975  Sequential treatment assignment with balancing for 

prognostic factors in controlled clinical trials. Biometrics 31(1):103-115. 

Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Simms L, 
Posther Sugarman K, Obasaju C, Blatter J. 2007. Phase III study of pemetrexed plus 
cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally 
advanced or metastatic non-small cell lung cancer (NSCLC). 12th World Conference 
on Lung Cancer. J Thorac Oncol 2(8 Suppl 4):S306. Abstract PRS-03. 

Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, 

Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park 
K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. 
2008. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus 
pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung 
cancer. J Clin Oncol 26(21): [Epub ahead of print on May 27, 2008.] 

Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, 
Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, 
Beardsley GP, Kohler W, Ratnam M, Schultz RM. 1997. LY231514, a pyrrolo[2,3-

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 64 

d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer 
Res 57(6):1116-1123. 

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, 

Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. 2000. New 
guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 
92(3):205-216. 

Theti DS, Jackman AL. 2004. The role of alpha-folate receptor-mediated transport in the 

antitumor activity of antifolate drugs. Clin Cancer Res 10(3):1080-1089. 

Veronesi A, Zagonel V, Tirelli U, Galligioni E, Tumolo S, Barzan L, Lorenzini M, 

Comoretto R, Grigoletto E. 1985. High-dose versus low-dose cisplatin in advanced 
head and neck squamous carcinoma: a randomized study. J Clin Oncol 3(8):1105-1108. 

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier 

U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. 2003. Phase III study of 
pemetrexed in combination with cisplatin versus cisplatin alone in patients with 
malignant pleural mesothelioma. J Clin Oncol 21(14):2636-2644. 

Yost KJ, Eton DT. 2005. Combining distribution- and anchor-based approaches to 

determine minimally important differences: the FACIT experience. Eval Health Prof 
28(2):172-91. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 66 

Footnotes for Study Schedule, Protocol H3E-MC-JMHR(b) (Continued) 

Abbreviations:  BL = baseline, CrCl = creatinine clearance; CRF = case report form; CT = computed 
tomography; CTCAE = Common Terminology Criteria for Adverse Events; dc = discontinuation; 
ECOG = Eastern Cooperative Oncology Group; FACT-H&N = Functional Assessment of Cancer 
Therapy for Head and Neck Cancer; FFPE = formalin-fixed, paraffin-embedded; G-CSF = granulocyte 
colony-stimulating factor; GM-CSF = granulocyte-macrophage colony-stimulating factor; MRI = 
magnetic resonance imaging. 

a  See Section 5.5 for exceptions to timing of doses.  Patients will continue cycles of therapy until disease 

progression or until the patient meets criteria for study treatment discontinuation. 

b  Postdiscontinuation visit is approximately 30 days after patient discontinuation from the treatment 

portion of the study, rather than after the last dose of the study drug. 

  Following 30-day postdiscontinuation visit and objective disease progression, patients will be followed 

every 90 days (±14 days).  Data collected will include:  date of disease progression; any anticancer 
treatment including the dates of any postdiscontinuation systemic therapy, radiotherapy, or surgical 
intervention; and the date of death.  The date of first documented disease progression must be recorded 
on the CRF even if it occurs after the patient has started a new therapy.  Patients will be followed until 
death or study closure. 

c  Before the infusion. 
d  Physical examination will include measurements of height (at baseline only) and weight. 
e  Female patients with childbearing potential must have a negative urine or serum pregnancy test within 7 

days prior to study enrollment. 

f  Record key concomitant medications or growth factors (including G-CSF, GM-CSF, erythropoietin, 

antibiotics, and any nonstudy vitamin supplementation) and information related to transfusions at every 
cycle including the 30-day postdiscontinuation visit. 

g  Visual measurements (for palpable lesions) must be performed using a metric ruler or calipers, and a 

color medical photograph must be taken   For radiologic tests, CT (including spiral CT) scans and MRI 
are the preferred methods of measurement, but chest x-ray is acceptable if the lesion(s) is/are clearly 
defined and surrounded by aerated lung   Investigators must consistently use the same imaging 
modality. 
 
 
 
 
 
 
 
 
 
 

Baseline (palpable le ions):  Within 2 weeks before the first dose of study treatment. 
Baseline (radiological):  Within 4 weeks before first dose of study treatment. 
During study treatment:  Before the infusion.  Palpable lesion measurements and radiological 
assessments should be completed approximately every 6 weeks (±2 weeks) within 7 days of every 
other cycle of treatment; for example, after baseline, assessments should 
be repeated within 7 days prior to, or the day of, Day 1 of Cycle 3, Cycle 5, etc. 
Response confirmation:  Responses must be confirmed.  Confirmation should be performed 
≥ 28 days after initial response documentation and then every 6 weeks (±2 weeks). 
Postdiscontinuation follow-up period:  Every 6 weeks (±2 weeks) until objective disease 
progression based on lesion measurements.  Thereafter, repeated as clinically indicated.  

 
 
 
 
 
 
 
 
 
 
h  Chemistry and Hematology: 

Baseline:  ≤ 7 days prior to Day 1 of Cycle 1. 
Cycle 1, Day 15:  All patients will have blood collected during Cycle 1, on Day 15 ±3 days 
During study treatment:  ≤ 3 days prior to Day 1 of each cycle.   
Additional chemistry and hematology values may be collected during study treatment cycles 
per local practice guidelines.  Investigators must document their review of each laboratory report. 
Postdiscontinuation visit:  ~ 30 days after patient discontinuation from the treatment portion of 

the study, rather than after the last dose of the study drug. 

 
 
 
 
 

 
 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

(continued) 

Protocol Amendment 

Redacted Version Page 67 

Footnotes for Study Schedule, Protocol H3E-MC-JMHR(b) (Concluded) 

i  Calculated CrCl:  ≤ 7 days prior to Day 1 of Cycle 1 and ≤ 3 days prior to Day 1 of subsequent cycles. 

The CrCl does not need to be calculated at the postdiscontinuation visit.  

j  Grade adverse events using the CTCAE scale before each cycle and at the 30-day postdiscontinuation 

visit (Version 3.0, NCI 2003). 

k  Daily, beginning approximately 7 to 14 days before the first dose of pemetrexed and continuing daily 

until 3 weeks after the last dose of study therapy. 

l  Given as an intramuscular injection within approximately 7 to 14 days before the first dose of study 

treatment and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy. 

m  Dexamethasone (or equivalent): taken twice a day the day before, the day of, and the day after study 

treatment. 

n  Baseline: ≤ 7 days prior to randomization. 
  During study treatment:  prior to infusion at every cycle (except Cycle 1), on approximately Day 21 of 

the previous cycle, not to be repeated in case of cycle delays. 
At study discontinuation:  (may be conducted via telephone) 
Postdiscontinuation: 
 
 
 
 

○  postdiscontinuation visit:  approximately 30 days after patient discontinuation from the 
     treatment portion of the study, rather than after the last dose of the study drug. 
 
○  if patient discontinued from study treatment prior to disease progression:  repeat every 
     6 weeks until disease progression. 

o  A sample of pretreated FFPE tumor tissue should be prepared according to instructions provided by the 

central laboratory.  Study personnel will ship FFPE  issue sample to the central laboratory within 4 
weeks of randomization. 

 
 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 68 

Protocol Attachment JMHR.2. 

Clinical Laboratory Tests 

Clinical Laboratory Tests 

 

Hematologya: 

Hemoglobin (Hgb) 
 
Leukocytes (WBC) 
Platelets (PLTs) 
Neutrophils (sum of segmented and bands) 
 
 

Serum Pregnancy Testb 

Serum or Urine Pregnancy Testa, d 

 
 
Translational Researchb 

Pretreatment FFPE tumor tissue sample 
 

 

Clinical Chemistrya, b:  

Total bilirubin 
Alkaline phosphatase (ALP) 
Alanine aminotransferase (ALT/SGPT) 
Aspartate aminotransferase (AST/SGOT) 
Blood urea nitrogen (BUN) 
Serum creatinine 
Calculated creatinine clearance (CrCl)c, d 
 
Sodium 
Potassium 
Magnesium 
 
 

Abbreviations:  FFPE = formalin-fixed, paraffin-embedded; WBC = white blood cell. 
a  Assayed by local laboratory. 
b  Assayed by central laboratory. 
c  See Protocol Attachment JMHR.4  
d  If used for enrollment or dosing decisions, the local laboratory will perform certain chemistries, serum 

or urine pregnancy test, and CrCl. 

 

Note:  Patients may be enrolled and randomized on the basis of local chemistries and 
CrCl only if the central laboratory values are not available (if local CrCl is used, the 
same local lab must be used throughout the study).  However, a specimen must be 
collected prior to the initiation of treatment and sent to the central laboratory for blood 
chemistries.  If local blood chemistry values are used for subsequent dosing decisions, 
specimens must still be collected and sent to the central laboratory.  These central 
laboratory results will be used for subsequent safety analyses. 

Additional chemistry and hematology values may be collected during study treatment 
cycles per local practice guidelines.  Investigators must document their review of each 
laboratory report. 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 69 

Protocol Attachment JMHR.3. 

Eastern Cooperative Oncology Group (ECOG) 

Performance Status Scale 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 70 

Protocol Attachment JMHR.3 

ECOG Performance Status Scale 

Description 

 

Fully active, able to carry on all pre-disease performance without 
restriction. 
 
Restricted in physically strenuous activity but ambulatory and able 
to carry out work of a light or sedentary nature, eg, light housework, 
office work. 
 
Ambulatory and capable of all self-care but unable to carry out any 
work activities.  Up and about more than 50% of waking hours. 
 
Capable of only limited self-care, confined to bed or chair more than 
50% of waking hours. 
 
Completely disabled.  Cannot carry on any self-care.   Totally 
confined to bed or chair. 
 
Dead 
 

 

Grade 
 

0 

1 

2 

3 

4 

5 

(from Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. 1982. Toxicity 

and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655). 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Protocol Attachment JMHR.4. 

Creatinine Clearance Assay Methods 

Page 71 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 72 

Protocol Attachment JMHR.4. 

Creatinine Clearance Assay Methods 

Creatinine clearance calculation in this study will be based on any the following assay 
methods: 

1)  The standard Cockcroft and Gault formula (1976) 

Note:  This formula is to be used for calculating CrCl from local lab results only.  
Central laboratory applies the formula and reports the value in its calculated form.   

 

 
 
CrCl (mL/min)  = 

 
 
 
CrCl (mL/min) = 

For serum creatinine concentration in mg/dL: 
  (140 – age+) × (wt+)  ×  (0.85 for women*) 

72 × serum creatinine (mg/dL) 

 
For serum creatinine concentration in µmol/L: 
   (140 – age+) × (wt+)  ×  (0.85 for women*) 

0.81 × serum creatinine (µmol/L) 

Abbreviation: CrCl = creatinine clearance. 
+age in years, weight (wt) in kilograms. 
*factor is 1.0 for men. 
Cockcroft and Gault 1976. 
 

2)  Glomerular filtration rate (GFR) as measured by a 24-hour urine 

sample. 

3)  Glomerular filtration rate (GFR) as measured by the appropriate 

radiolabeled method (51-CrEDTA or Tc99m-DTPA). 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 73 

Protocol Attachment JMHR.5. 

RECIST Guidelines 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 74 

Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines 

Protocol Attachment JMHR.5 

(Therasse et al. 2000) 

Measurability of Tumor Lesions at Baseline: 

Measurable lesions - lesions that can be accurately measured in at least one dimension 
as ≥ 20 mm with conventional techniques or as  ≥ 10mm with spiral CT scan (longest 
diameter to be recorded).  

Nonmeasurable lesions -  all other lesions, including small lesions (longest diameter <20 
mm with conventional techniques or <10 mm with spiral CT scan) and truly 
nonmeasurable lesions.  Lesions considered to be truly nonmeasurable include the 
following:  bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, 
inflammatory breast disease, lymphangitis cutis/pulmonis, abdominal masses that are not 
confirmed and followed by imaging techniques, and cystic lesions. 

Documentation of “target” and “nontarget” lesions at Baseline: 

All tumor measurements will be recorded in centimeters using a ruler or calipers.  All 
baseline evaluations should be performed as close as possible to the start of treatment but 
never more than 28 days before beginning treatment. 

Target - All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions 
in total, representative of all involved organs, should be identified as target lesions and 
recorded and measured at baseline.  Target lesions should be selected on the basis of their 
size (those with the longest diameter) and their suitability for accurate repeated 
measurements (either by imaging techniques or clinically).  If the measurable disease is 
restricted to a solitary lesion, its neoplastic nature should be confirmed by 
cytology/histology. 

A sum of the longest diameter for all target lesions will be calculated and reported as the 
baseline sum longest diameter.  The baseline sum longest diameter will be used as the 
reference by which to characterize the objective tumor response. 

Nontarget – All other lesions (or sites of disease) including small lesions (longest 
diameter <20 mm with conventional CT scan, <10 mm with spiral CT scan) and other 
non-measurable lesions should be identified as nontarget lesions and should be recorded 
at baseline.  Measurement of these lesions are not required, but the presence of absence 
of each should be noted throughout follow-up. 

Method of Measurement 

The same method of measurement and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow-up.  Computerized 
tomography (CT), or magnetic resonance imaging (MRI), should be performed with cuts 
of 10 mm or less in slice thickness contiguously.  Spiral CT should be performed using a 
5 mm contiguous reconstruction algorithm.  This applies to the chest, abdomen, and 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 75 

pelvis.  Chest X-ray is acceptable as measurable lesions when they are clearly defined 
and surrounded by aerated lung.  However, CT scan or MRI is preferred.    

Clinical lesions will only be considered measurable when they are superficial  (for 
example, skin nodules or palpable lymph nodes).  For the case of skin lesions, 
documentation by color photography including a ruler to estimate the size of the lesion is 
recommended. 

Timing of Subsequent Tumor Assessments 

Radiological and physical assessments will be routinely repeated before drug 
administration at every other cycle throughout the treatment period and at follow-up 
visits (as specified in the Schedule of Events, Protocol Attachment JMHR.1).  All areas 
of disease must be re-evaluated at each subsequent assessment.  The same technique used 
at baseline must be used.  Chest x-rays are acceptable for a subsequent assessment if used 
at baseline, however CT scan or MRI is preferred.  

If the patient’s disease has responded to therapy, the investigator must confirm the 
response.  It is recommended that confirmation of response occur ≥28 days and ≤42 days 
after the first evidence of response using the same radiological technique as at baseline.  
The baseline sum of longest diameters of target lesions will be used as reference for 
confirmation of response. 

Both measurable and nonmeasurable lesions should be evaluated at each restaging to 
determine whether they have completely resolved or persisted, or whether new lesions 
have appeared. 

Response Criteria: 

Patients will be assessed using the following criteria: 

•  Complete response (CR): Disappearance of all tumor lesions. 
•  Partial response (PR): Either a) at least a 30% decrease in the sum of 

the longest diameter (LD) of target lesions taking as reference the 
baseline sum LDs or b) complete disappearance of target lesions, with 
persistence (but not worsening) of one or more nontarget lesions.  In 
either case, no new lesions may have appeared.  

•  Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor 

sufficient increase to qualify for PD taking as references the smallest 
sum LD. 

•  Progressive disease (PD): At least a 20% increase in the sum of LD 
of target lesions taking as references the smallest sum LD recorded 
since the treatment started or the appearance of one or more new 
lesions. 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 76 

•  Unknown:  Progression has not been documented and one or more 

target or nontarget sites have not been assessed. 

Overall Responses for All Possible Combinations of Tumor Responses in Target and 
Nontarget Lesions with Or without the Appearance of New Lesions. 

Target 
Lesions 
CR 
CR 
PR 
SD 
PD 
Any 
Any 

Nontarget Lesions 

New Lesions 

Overall Response 

CR 
Incomplete response/SD 
Non-PD 
Non-PD 
Any 
PD 
Any 

No 
No 
No 
No 
Yes or no 
Yes or no 
Yes 

CR 
PR 
PR 
SD 
PD 
PD 
PD 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 77 

Protocol Attachment JMHR.6. 

Functional Assessment of Cancer Therapy - 

Head and Neck Cancer (FACT-H&N) 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 78 

Protocol Attachment JMHR.6 

Fact-H&N (Version 4) 

Below is a list of statements that other people with your illness have said are important.  
By circling one (1) number per line, please indicate how true each statement has 
been for you during the past 7 days. 

 

not 

a little 

some- 

quite 

very 

 at all 

  bit 

what 

a bit 

much 

1 

1 

1 

1 

1 

1 

1 

2 

2 

2 

2 

2 

2 

2 

3 

3 

3 

3 

3 

3 

3 

4 

4 

4 

4 

4 

4 

4 

a little 

some- 

quite 

very 

what 

a bit 

much 

1 

1 

1 

1 

1 

1 

2 

2 

2 

2 

2 

2 

3 

3 

3 

3 

3 

3 

4  

4 

4 

4 

4 

4 

PHYSICAL WELL-BEING  
 
 

 

 

 

GP1. I have a lack of energy   

GP2.  I have nausea 

 

 

 

 

 

 

 

 

0 

0 

GP3. Because of my physical condition, I have trouble 
   meeting the needs of my family 
0 

 

 

GP4. I have pain 

 

 

 

 

GP5. I am bothered by side effects of treatment 

GP6. I feel ill   

 

 

 

GP7. I am forced to spend time in bed 

SOCIAL/FAMILY WELL-BEING  
 
 

 

 

 

 

GS1. I feel close to my friends 

 

 

 

 
 at all 

 

GS2. I get emotional support from my family 

GS3. I get support from my friends 

 

GS4. My family has accepted my illness 

 

 

0 

0 

0 

0 

not 

  bit 

0 

0 

0 

0 

GS5. I am satisfied with family communication about my 
   illness 

0 

 

 

 

 

 

GS6. I feel close to my partner  
(or the person who is my main support) 

 

 

0 

Regardless of your current level of sexual activity, please answer the following question.  
If you prefer not to answer it, please check this box  and go to the next section. 

GS7. I am satisfied with my sex life   

 

0 

1 

2 

3 

4 

 
 

 

US English 
Copyright 1987, 1997 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version By circling one (1) number per line, please indicate how true each statement has 
been for you during the past 7 days. 

Page 79 

EMOTIONAL WELL-BEING 
 

 

 

 

 

GE1. I feel sad0 

 

 

 
 

 

 
 

 

GE2. I am satisfied with how I am coping with my  
   illness 

 

 

 

 

 

GE3. I am losing hope in the fight against my  
   illness 
 

 

 

 

 

GE4. I feel nervous 

 

GE5. I worry about dying 

 

 

 

 

 

 

GE6. I worry that my condition will get worse 

FUNCTIONAL WELL-BEING  

not 

a little 

some- 

quite 

at all 

  bit 

what 

a bit 

very 
much 

0 

0 

0 

0 

0 

0 

1 

1 

1 

1 

1 

1 

2 

2 

2 

2 

2 

2 

3 

3 

3 

3 

3 

3 

4 

4 

4 

4 

4 

4 

not 

a little 

some- 

quite 

at all 

  bit 

what 

a bit 

very 
much 

GF1.I am able to work (include work at home) 

0 

GF2. My work (include work at home) is fulfilling  0 

GF3. I am able to enjoy life 

 

GF4. I have accepted my illness 

GF5. I am sleeping well 

 

 

 

 

 

 

 

0 

0 

0 

GF6. I am enjoying the things I usually do for fun  0 

GF7. I am content with the quality of my life right 
    now  

 

 

 

 

 

0 

1 

1 

1 

1 

1 

1 

1 

2 

2 

2 

2 

2 

2 

2 

3 

3 

3 

3 

3 

3 

3 

4 

4 

4 

4 

4 

4 

4 

 

 

 

 
 

 

 

US English 
Copyright 1987, 1997 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version By circling one (1) number per line, please indicate how true each statement has 
been for you during the past 7 days. 

ADDITIONAL CONCERNS 

not 

a little 

some- 

quite 

at all 

 bit 

what 

 a bit 

very 
much 

Page 80 

1 

1 

1 

1 

1 

1 

1 

1 

1 

1 

1 

1 

2 

2 

2 

2 

2 

2 

2 

2 

2 

2 

2 

2 

3 

3 

3 

3 

3 

3 

3 

3 

3 

3 

3 

3 

4 

4 

4 

4 

4 

4 

4 

4 

4 

4 

4 

4 

H&N1. I am able to eat the foods that I like   

H&N2. My mouth is dry 

 

H&N3. I have trouble breathing 

 

 

 

 

0 

0 

0 

H&N4. My voice has its usual quality and strength  0 

H&N5. I am able to eat as much food as I want 

H&N6. I am unhappy with how my face and neck 
   look   

 

 

 

 

 

H&N7. I can swallow naturally and easily 

H&N8. I smoke cigarettes or other tobacco 
   products 

 

 

 

 

 

 

H&N9. I drink alcohol (e.g. beer, wine, etc.)  

H&N10. I am able to communicate with others 

H&N11. I can eat solid foods  

 

 

0 

0 

0 

0 

0 

0 

0 

H&N12. I have pain in my mouth, throat, or neck  0 

 

 

 

 

 

 

 

 

US English 
Copyright 1987, 1997 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 81 

Protocol Attachment JMHR.7. 
Formula for Conditional Power 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version Page 82 

Protocol Attachment JMHR.7. 
Formula for Conditional Power 

 

Let I be the number of PFS events at the interim analysis, F the number of PFS events at 
the final analysis, and ZI the value of the standard normal interim test statistic under H0.  
Then for testing H0 (conditional on ZI with true HR = y): 

Power  =  1 – Φ[(Zα/2 + ZI (I/F)1/2 – (1–I/F)(0.5)(F)1/2 log(1/y)) / (1–I/F)1/2]. 
 

Zα/2  is the upper 100th(1-α/2) percentile of the standard normal distribution; y is 
the true PFS hazard ratio of Pemetrexed plus Cisplatin relative to Placebo plus 
Cisplatin; where Φ is the standard normal distribution function. 

 

 

Pemetrexed H3E-MC-JMHR(b) 
Confidential 

Protocol Amendment 

Redacted Version 